2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Calkins, 2018, 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary, Europace, 20, 157, 10.1093/europace/eux275

Charitos, 2012, A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions, Circulation, 126, 806, 10.1161/CIRCULATIONAHA.112.098079

Gorenek, 2018, European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS, Europace, 20, 895, 10.1093/europace/euy051

Freedman, 2017, Management of atrial high-rate episodes detected by cardiac implanted electronic devices, Nat Rev Cardiol, 14, 701, 10.1038/nrcardio.2017.94

Perino, 2019, Practice variation in anticoagulation prescription and outcomes after device-detected atrial fibrillation, Circulation, 139, 2502, 10.1161/CIRCULATIONAHA.118.038988

Steinberg, 2018, Thirty-second gold standard definition of atrial fibrillation and its relationship with subsequent arrhythmia patterns: analysis of a large prospective device database, Circ Arrhythm Electrophysiol, 11, e006274, 10.1161/CIRCEP.118.006274

Camm, 2017, Atrial high-rate episodes and stroke prevention, Europace, 19, 169, 10.1093/europace/euw279

Pollak, 2001, Clinical utility of intraatrial pacemaker stored electrograms to diagnose atrial fibrillation and flutter, Pacing Clin Electrophysiol, 24, 424, 10.1046/j.1460-9592.2001.00424.x

Kaufman, 2012, Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT, Heart Rhythm, 9, 1241, 10.1016/j.hrthm.2012.03.017

Benjamin, 2019, Heart disease and stroke statistics – 2019 update: a report from the American Heart Association, Circulation, 139, e56, 10.1161/CIR.0000000000000659

Chugh, 2014, Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study, Circulation, 129, 837, 10.1161/CIRCULATIONAHA.113.005119

Colilla, 2013, Estimates of current and future incidence and prevalence of atrial fibrillation in the US adult population, Am J Cardiol, 112, 1142, 10.1016/j.amjcard.2013.05.063

Krijthe, 2013, Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060, Eur Heart J, 34, 2746, 10.1093/eurheartj/eht280

Dewland, 2013, Incident atrial fibrillation among Asians, Hispanics, blacks, and whites, Circulation, 128, 2470, 10.1161/CIRCULATIONAHA.113.002449

Staerk, 2017, Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes, Circ Res, 120, 1501, 10.1161/CIRCRESAHA.117.309732

Alonso, 2009, Incidence of atrial fibrillation in whites and African Americans: the Atherosclerosis Risk in Communities (ARIC) study, Am Heart J, 158, 111, 10.1016/j.ahj.2009.05.010

Chao, 2018, Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan Nationwide AF Cohort Study, Chest, 153, 453, 10.1016/j.chest.2017.10.001

Guo, 2015, Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation, Chest, 147, 109, 10.1378/chest.14-0321

Di Carlo, 2019, Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project, Europace, 21, 1468, 10.1093/europace/euz141

Mou, 2018, Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC study (Atherosclerosis Risk in Communities, Circ Arrhythm Electrophysiol, 11, e006350, 10.1161/CIRCEP.118.006350

Boriani, 2015, Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making – a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society, Europace, 17, 1169, 10.1093/europace/euv202

Aune, 2018, Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies, J Diabetes Complications, 32, 501, 10.1016/j.jdiacomp.2018.02.004

Cadby, 2015, Severity of OSA is an independent predictor of incident atrial fibrillation hospitalization in a large sleep-clinic cohort, Chest, 148, 945, 10.1378/chest.15-0229

Hobbelt, 2017, Clinical, biomarker, and genetic predictors of specific types of atrial fibrillation in a community-based cohort: data of the PREVEND study, Europace, 19, 226

Nalliah, 2018, The impact of diet and lifestyle on atrial fibrillation, Curr Cardiol Rep, 20, 137, 10.1007/s11886-018-1082-8

Lip, 2017, Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE), Europace, 19, 891, 10.1093/europace/eux091

Gallagher, 2017, Alcohol and incident atrial fibrillation – a systematic review and meta-analysis, Int J Cardiol, 246, 46, 10.1016/j.ijcard.2017.05.133

Ricci, 2018, Physical activity volume in relation to risk of atrial fibrillation. A non-linear meta-regression analysis, Eur J Prev Cardiol, 25, 857, 10.1177/2047487318768026

Heeringa, 2006, Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study, Eur Heart J, 27, 949, 10.1093/eurheartj/ehi825

Lloyd-Jones, 2004, Lifetime risk for development of atrial fibrillation: the Framingham Heart Study, Circulation, 110, 1042, 10.1161/01.CIR.0000140263.20897.42

Magnussen, 2017, Sex differences and similarities in atrial fibrillation epidemiology, risk factors, and mortality in community cohorts: results from the BiomarCaRE Consortium (, Biomarker for Cardiovascular Risk Assessment in Europe). Circulation, 136, 1588

Staerk, 2018, Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study, BMJ, 361, k1453, 10.1136/bmj.k1453

Allan, 2017, Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants, Thromb Haemost, 117, 837, 10.1160/TH16-11-0825

Feghaly, 2018, Genetics of atrial fibrillation, J Am Heart Assoc, 7, e009884, 10.1161/JAHA.118.009884

Abdulla, 2009, Is the risk of atrial fibrillation higher in athletes than in the general population? A systematic review and meta-analysis, Europace, 11, 1156, 10.1093/europace/eup197

Alonso, 2014, Association of sick sinus syndrome with incident cardiovascular disease and mortality: the Atherosclerosis Risk in Communities Study and Cardiovascular Health Study, PLoS One, 9, e109662, 10.1371/journal.pone.0109662

Alonso, 2011, Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 123, 2946, 10.1161/CIRCULATIONAHA.111.020982

Andersen, 2013, Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study, Eur Heart J, 34, 3624, 10.1093/eurheartj/eht188

Asad, 2018, Obesity is associated with incident atrial fibrillation independent of gender: a meta-analysis, J Cardiovasc Electrophysiol, 29, 725, 10.1111/jce.13458

Aune, 2017, Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies, Eur J Epidemiol, 32, 181, 10.1007/s10654-017-0232-4

Bansal, 2017, eGFR and albuminuria in relation to risk of incident atrial fibrillation: a meta-analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study, Clin J Am Soc Nephrol, 12, 1386, 10.2215/CJN.01860217

Baumgartner, 2017, Thyroid Studies Collaboration. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation, Circulation, 136, 2100, 10.1161/CIRCULATIONAHA.117.028753

Benjamin, 1994, Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study, JAMA, 271, 840, 10.1001/jama.1994.03510350050036

Bunch, 2015, Long-term natural history of adult Wolff-Parkinson-White syndrome patients treated with and without catheter ablation, Circ Arrhythm Electrophysiol, 8, 1465, 10.1161/CIRCEP.115.003013

Chang, 2017, Association of a family history of atrial fibrillation with incidence and outcomes of atrial fibrillation: a population-based family cohort study, JAMA Cardiol, 2, 863, 10.1001/jamacardio.2017.1855

Chen, 2016, Carotid intima-media thickness and arterial stiffness and the risk of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study, Multi-Ethnic Study of Atherosclerosis (MESA), and the Rotterdam Study, J Am Heart Assoc, 5, 10.1161/JAHA.115.002907

Cheng, 2014, Caffeine intake and atrial fibrillation incidence: dose response meta-analysis of prospective cohort studies, Can J Cardiol, 30, 448, 10.1016/j.cjca.2013.12.026

Cheng, 2009, Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block, JAMA, 301, 2571, 10.1001/jama.2009.888

Conen, 2010, Caffeine consumption and incident atrial fibrillation in women, Am J Clin Nutr, 92, 509, 10.3945/ajcn.2010.29627

Desai, 2019, The burden and impact of arrhythmia in chronic obstructive pulmonary disease: insights from the National Inpatient Sample, Int J Cardiol, 281, 49, 10.1016/j.ijcard.2019.01.074

Eaker, 2004, Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study, Circulation, 109, 1267, 10.1161/01.CIR.0000118535.15205.8F

Fox, 2004, Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring, JAMA, 291, 2851, 10.1001/jama.291.23.2851

Furberg, 1994, Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study), Am J Cardiol, 74, 236, 10.1016/0002-9149(94)90363-8

Giacomantonio, 2013, A systematic review of the health benefits of exercise rehabilitation in persons living with atrial fibrillation, Can J Cardiol, 29, 483, 10.1016/j.cjca.2012.07.003

Kirchhof, 2012, Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options – a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference, Europace, 14, 8, 10.1093/europace/eur241

Ko, 2019, Proteomics profiling and risk of new-onset atrial fibrillation: Framingham Heart Study, J Am Heart Assoc, 8, e010976, 10.1161/JAHA.118.010976

Kwok, 2014, Physical activity and incidence of atrial fibrillation: a systematic review and meta-analysis, Int J Cardiol, 177, 467, 10.1016/j.ijcard.2014.09.104

Lip, 2017, Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE), Thromb Haemost, 117, 2215, 10.1160/TH-17-10-0709

Loomba, 2017, Arrhythmias in adults with congenital heart disease: what are risk factors for specific arrhythmias?, Pacing Clin Electrophysiol, 40, 353, 10.1111/pace.12983

Lubitz, 2010, Association between familial atrial fibrillation and risk of new-onset atrial fibrillation, JAMA, 304, 2263, 10.1001/jama.2010.1690

May, 2016, Outcomes of Sleep Disorders in Older Men) Study Group. Central sleep-disordered breathing predicts incident atrial fibrillation in older men, Am J Respir Crit Care Med, 193, 783, 10.1164/rccm.201508-1523OC

Michniewicz, 2018, Patients with atrial fibrillation and coronary artery disease – double trouble, Adv Med Sci, 63, 30, 10.1016/j.advms.2017.06.005

Monrad, 2017, Long-term exposure to traffic-related air pollution and risk of incident atrial fibrillation: a cohort study, Environ Health Perspect, 125, 422, 10.1289/EHP392

O'Neal, 2015, Coronary artery calcium progression and atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis, Circ Cardiovasc Imaging, 8

Qureshi, 2015, Al-Mallah MH. Cardiorespiratory fitness and risk of incident atrial fibrillation: results from the Henry Ford Exercise Testing (FIT) Project, Circulation, 131, 1827, 10.1161/CIRCULATIONAHA.114.014833

Santhanakrishnan, 2016, Atrial fibrillation begets heart failure and vice versa: temporal associations and differences in preserved versus reduced ejection fraction, Circulation, 133, 484, 10.1161/CIRCULATIONAHA.115.018614

Schnabel, 2015, 50-Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study, Lancet, 386, 154, 10.1016/S0140-6736(14)61774-8

Shen, 2011, Dietary factors and incident atrial fibrillation: the Framingham Heart Study, Am J Clin Nutr, 93, 261, 10.3945/ajcn.110.001305

Svensson, 2017, Psychological stress and risk of incident atrial fibrillation in men and women with known atrial fibrillation genetic risk scores, Sci Rep, 7, 42613, 10.1038/srep42613

Tung, 2017, Obstructive and central sleep apnea and the risk of incident atrial fibrillation in a community cohort of men and women, J Am Heart Assoc, 6, 10.1161/JAHA.116.004500

Walkey, 2013, Atrial fibrillation among Medicare beneficiaries hospitalized with sepsis: incidence and risk factors, Am Heart J, 165, 949, 10.1016/j.ahj.2013.03.020

Zoller, 2012, High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden, J Am Heart Assoc, 2, e003384, 10.1161/JAHA.112.003384

Lip, 2020, Evaluation of the C2HEST risk score as a possible opportunistic screening tool for incident atrial fibrillation in a healthy population (from a nationwide Danish cohort study), Am J Cardiol, 125, 48, 10.1016/j.amjcard.2019.09.034

Yiin, 2018, Time trends in atrial fibrillation-associated stroke and premorbid anticoagulation, Stroke, STROKEAHA118022249

Akao, 2013, Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry, J Cardiol, 61, 260, 10.1016/j.jjcc.2012.12.002

An, 2019, Causes of death in Japanese patients with atrial fibrillation: the Fushimi Atrial Fibrillation Registry, Eur Heart J Qual Care Clin Outcomes, 5, 35, 10.1093/ehjqcco/qcy033

Andersson, 2013, All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case-control study, Eur Heart J, 34, 1061, 10.1093/eurheartj/ehs469

Andrew, 2013, The prevalence, impact and economic implications of atrial fibrillation in stroke: what progress has been made?, Neuroepidemiology, 40, 227, 10.1159/000343667

Bakhai, 2016, Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry, Eur Heart J Qual Care Clin Outcomes, 2, 299, 10.1093/ehjqcco/qcw031

Benjamin, 1998, Impact of atrial fibrillation on the risk of death: the Framingham Heart Study, Circulation, 98, 946, 10.1161/01.CIR.98.10.946

Blum, 2017, Prospective assessment of sex-related differences in symptom status and health perception among patients with atrial fibrillation, J Am Heart Assoc, 6, e005401, 10.1161/JAHA.116.005401

Boriani, 2015, Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry, Am J Med, 128, 509, 10.1016/j.amjmed.2014.11.026

Ceornodolea, 2017, Epidemiology and management of atrial fibrillation and stroke: review of data from four European countries, Stroke Res Treat, 2017, 8593207

Chao, 2016, Validation of a modified CHA2DS2-VASc score for stroke risk stratification in Asian patients with atrial fibrillation: a nationwide cohort study, Stroke, 47, 2462, 10.1161/STROKEAHA.116.013880

Chao, 2015, Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?, J Am Coll Cardiol, 65, 635, 10.1016/j.jacc.2014.11.046

Dagres, 2018, European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?, EP Europace, 20, 1399, 10.1093/europace/euy046

Esato, 2017, Clinical impact of asymptomatic presentation status in patients with paroxysmal and sustained atrial fibrillation: the Fushimi AF Registry, Chest, 152, 1266, 10.1016/j.chest.2017.08.004

Freeman, 2015, Association between atrial fibrillation symptoms, quality of life, and patient outcomes: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), Circ Cardiovasc Qual Outcomes, 8, 393, 10.1161/CIRCOUTCOMES.114.001303

Frost, 2001, Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation, Arch Intern Med, 161, 272, 10.1001/archinte.161.2.272

Gaita, 2013, Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function, J Am Coll Cardiol, 62, 1990, 10.1016/j.jacc.2013.05.074

Garcia-Fernandez, 2017, Applicability of the modified CHA2DS2-VASc score for stroke risk stratification in Caucasian atrial fibrillation patients, Eur J Intern Med, 38, e21, 10.1016/j.ejim.2016.11.006

Gleason, 2018, Atrial fibrillation symptoms and sex, race, and psychological distress: a literature review, J Cardiovasc Nurs, 33, 137, 10.1097/JCN.0000000000000421

Gomez-Outes, 2016, Causes of death in anticoagulated patients with atrial fibrillation, J Am Coll Cardiol, 68, 2508, 10.1016/j.jacc.2016.09.944

Graves, 2017, Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long-term warfarin, Am Heart J, 188, 93, 10.1016/j.ahj.2017.02.026

John, 2018, Atrial fibrillation hospitalization, mortality, and therapy, Eur Heart J, 39, 3958, 10.1093/eurheartj/ehy622

Kalantarian, 2016, Atrial fibrillation and cognitive decline: phenomenon or epiphenomenon?, Cardiol Clin, 34, 279, 10.1016/j.ccl.2015.12.011

Kalantarian, 2013, Cognitive impairment associated with atrial fibrillation: a meta-analysis, Ann Intern Med, 158, 338, 10.7326/0003-4819-158-5-201303050-00007

Kim, 2011, Estimation of total incremental health care costs in patients with atrial fibrillation in the United States, Circ Cardiovasc Qual Outcomes, 4, 313, 10.1161/CIRCOUTCOMES.110.958165

Kirchhof, 2014, Management of patients with atrial fibrillation by primary-care physicians in Germany: 1-year results of the ATRIUM registry, Clin Cardiol, 37, 277, 10.1002/clc.22272

Kochhauser, 2016, The impact of duration of atrial fibrillation recurrences on measures of health-related quality of life and symptoms, Pacing Clin Electrophysiol, 39, 166, 10.1111/pace.12772

Konig, 2018, In-hospital mortality of patients with atrial arrhythmias: insights from the German-wide Helios hospital network of 161 502 patients and 34 025 arrhythmia-related procedures, Eur Heart J, 39, 3947, 10.1093/eurheartj/ehy528

Kotecha, 2016, Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins, J Am Coll Cardiol, 68, 2217, 10.1016/j.jacc.2016.08.048

Kupper, 2018, Type D personality affects health-related quality of life in patients with lone atrial fibrillation by increasing symptoms related to sympathetic activation, J Psychosom Res, 115, 44, 10.1016/j.jpsychores.2018.10.005

Kwok, 2011, Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis, Neurology, 76, 914, 10.1212/WNL.0b013e31820f2e38

Levy, 1999, Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists, Circulation, 99, 3028, 10.1161/01.CIR.99.23.3028

Lin, 1996, Stroke severity in atrial fibrillation. The Framingham Study, Stroke, 27, 1760, 10.1161/01.STR.27.10.1760

Lip, 2015, Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot Survey on Atrial Fibrillation, Europace, 17, 24, 10.1093/europace/euu155

McCabe, 2015, Patients’ experiences from symptom onset to initial treatment for atrial fibrillation, J Clin Nurs, 24, 786, 10.1111/jocn.12708

McCabe, 2011, Living with atrial fibrillation: a qualitative study, J Cardiovasc Nurs, 26, 336, 10.1097/JCN.0b013e31820019b9

Meyre, 2019, Risk of hospital admissions in patients with atrial fibrillation: a systematic review and meta-analysis, Can J Cardiol, 35, 1332, 10.1016/j.cjca.2019.05.024

Nieuwlaat, 2005, Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation, Eur Heart J, 26, 2422, 10.1093/eurheartj/ehi505

Overvad, 2017, Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score, Eur Heart J Cardiovasc Pharmacother, 3, 37, 10.1093/ehjcvp/pvw022

Page, 1994, Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia, Circulation, 89, 224, 10.1161/01.CIR.89.1.224

Piccini, 2016, Rhythm control in atrial fibrillation, Lancet, 388, 829, 10.1016/S0140-6736(16)31277-6

Pistoia, 2016, The epidemiology of atrial fibrillation and stroke, Cardiol Clin, 34, 255, 10.1016/j.ccl.2015.12.002

Pokorney, 2016, Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF, J Am Heart Assoc, 5, e002197, 10.1161/JAHA.115.002197

Potpara, 2013, A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study, Int J Cardiol, 168, 4744, 10.1016/j.ijcard.2013.07.234

Randolph, 2016, Patient factors associated with quality of life in atrial fibrillation, Am Heart J, 182, 135, 10.1016/j.ahj.2016.08.003

Rienstra, 2012, Symptoms and functional status of patients with atrial fibrillation: state-of-the-art and future research opportunities, Circulation, 125, 2933, 10.1161/CIRCULATIONAHA.111.069450

Rienstra, 2014, Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study, Heart Rhythm, 11, 939, 10.1016/j.hrthm.2014.03.016

Rivard, 2017, Mechanisms, clinical significance, and prevention of cognitive impairment in patients with atrial fibrillation, Can J Cardiol, 33, 1556, 10.1016/j.cjca.2017.09.024

Santangeli, 2012, Atrial fibrillation and the risk of incident dementia: a meta-analysis, Heart Rhythm, 9, 1761, 10.1016/j.hrthm.2012.07.026

Schnabel, 2013, Depression in atrial fibrillation in the general population, PLoS One, 8, e79109, 10.1371/journal.pone.0079109

Schnabel, 2017, Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation, Heart, 103, 1024, 10.1136/heartjnl-2016-310406

Senoo, 2012, Distribution of first-detected atrial fibrillation patients without structural heart diseases in symptom classifications, Circ J, 76, 1020, 10.1253/circj.CJ-12-0105

Serpytis, 2018, Impact of atrial fibrillation on cognitive function, psychological distress, quality of life, and impulsiveness, Am J Med, 131, 703.e1-703, 10.1016/j.amjmed.2017.12.044

Siontis, 2016, Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: characteristics and prognostic implications, Heart Rhythm, 13, 1418, 10.1016/j.hrthm.2016.03.003

Steg, 2012, Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry, Heart, 98, 195, 10.1136/heartjnl-2011-300550

Steinberg, 2014, Drivers of hospitalization for patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), Am Heart J, 167, 735, 10.1016/j.ahj.2014.02.003

Stewart, 2002, A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study, Am J Med, 113, 359, 10.1016/S0002-9343(02)01236-6

Streur, 2017, Symptom clusters in adults with chronic atrial fibrillation, J Cardiovasc Nurs, 32, 296, 10.1097/JCN.0000000000000344

Thrall, 2007, Depression, anxiety, and quality of life in patients with atrial fibrillation, Chest, 132, 1259, 10.1378/chest.07-0036

Ugowe, 2019, Jackson LRn. Atrial fibrillation and mortality risk: seeing the big picture, Eur Heart J Qual Care Clin Outcomes, 5, 6, 10.1093/ehjqcco/qcy050

Vermond, 2014, Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study, Europace, 16, 1417, 10.1093/europace/euu151

Walters, 2018, Psychological distress and suicidal ideation in patients with atrial fibrillation: prevalence and response to management strategy, J Am Heart Assoc, 7, e005502, 10.1161/JAHA.117.005502

Walters, 2019, Symptom severity and quality of life in patients with atrial fibrillation: psychological function outweighs clinical predictors, Int J Cardiol, 279, 84, 10.1016/j.ijcard.2018.10.101

Wang, 2003, A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study, JAMA, 290, 1049, 10.1001/jama.290.8.1049

Wijesurendra, 2015, Atrial fibrillation: effects beyond the atrium?, Cardiovasc Res, 105, 238, 10.1093/cvr/cvv001

Xiong, 2015, Asymptomatic versus symptomatic atrial fibrillation: a systematic review of age/gender differences and cardiovascular outcomes, Int J Cardiol, 191, 172, 10.1016/j.ijcard.2015.05.011

Ziff, 2018, The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: insights from the United Kingdom ACALM registry, Int J Cardiol, 252, 117, 10.1016/j.ijcard.2017.06.033

Sepehri Shamloo, 2020, Atrial fibrillation and cognitive impairment: new insights and future directions, Heart Lung Circ, 29, 69, 10.1016/j.hlc.2019.05.185

Conen, 2019, Relationships of overt and silent brain lesions with cognitive function in patients with atrial fibrillation, J Am Coll Cardiol, 73, 989, 10.1016/j.jacc.2018.12.039

Kirchhof, 2016, 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur Heart J, 37, 2893, 10.1093/eurheartj/ehw210

Boriani, 2014, AF burden is important – fact or fiction?, Int J Clin Pract, 68, 444, 10.1111/ijcp.12326

Boriani, 2016, Atrial fibrillation burden and atrial fibrillation type: clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation, Vascul Pharmacol, 83, 26, 10.1016/j.vph.2016.03.006

Charitos, 2014, Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices, J Am Coll Cardiol, 63, 2840, 10.1016/j.jacc.2014.04.019

Wyse, 2014, Lone atrial fibrillation: does it exist?, J Am Coll Cardiol, 63, 1715, 10.1016/j.jacc.2014.01.023

Lip, 2017, Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE), Europace, 19, 1757, 10.1093/europace/eux240

January, 2019, 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation, Circulation, 140, e125, 10.1161/CIR.0000000000000665

Brieger, 2018, National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the diagnosis and management of atrial fibrillation 2018, Heart Lung Circ, 27, 1209, 10.1016/j.hlc.2018.06.1043

Chen, 2018, Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association, Circulation, 137, e623, 10.1161/CIR.0000000000000568

Ziegler, 2006, Comparison of continuous versus intermittent monitoring of atrial arrhythmias, Heart Rhythm, 3, 1445, 10.1016/j.hrthm.2006.07.030

Boriani, 2018, Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) long-term general registry, Europace, 20, 747, 10.1093/europace/eux301

Pandey, 2017, Predictors and prognostic implications of incident heart failure in patients with prevalent atrial fibrillation, JACC Heart Fail, 5, 44, 10.1016/j.jchf.2016.09.016

Ganesan, 2016, The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis, Eur Heart J, 37, 1591, 10.1093/eurheartj/ehw007

Al-Khatib, 2013, Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial, Eur Heart J, 34, 2464, 10.1093/eurheartj/eht135

Link, 2017, Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48, Circ Arrhythm Electrophysiol, 10, e004267, 10.1161/CIRCEP.116.004267

Steinberg, 2015, Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial, Eur Heart J, 36, 288, 10.1093/eurheartj/ehu359

Hart, 2000, Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators, J Am Coll Cardiol, 35, 183, 10.1016/S0735-1097(99)00489-1

Takabayashi, 2015, Incidence of stroke or systemic embolism in paroxysmal versus sustained atrial fibrillation: the Fushimi Atrial Fibrillation Registry, Stroke, 46, 3354, 10.1161/STROKEAHA.115.010947

Nieuwlaat, 2008, Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?, Eur Heart J, 29, 915, 10.1093/eurheartj/ehn101

Go, 2018, Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: the KP-RHYTHM Study, JAMA Cardiol, 3, 601, 10.1001/jamacardio.2018.1176

Ecker, 2018, A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation, Clin Cardiol, 41, 862, 10.1002/clc.22931

Nyong, 2016, Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation, Cochrane Database Syst Rev, 11, CD012088

Piccini, 2019, Atrial fibrillation burden, progression, and the risk of death: a case-crossover analysis in patients with cardiac implantable electronic devices, Europace, 21, 404, 10.1093/europace/euy222

Deng, 2017, Clinical scores for outcomes of rhythm control or arrhythmia progression in patients with atrial fibrillation: a systematic review, Clin Res Cardiol, 106, 813, 10.1007/s00392-017-1123-0

Healey, 2012, Subclinical atrial fibrillation and the risk of stroke, N Engl J Med, 366, 120, 10.1056/NEJMoa1105575

Potpara, 2012, A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation Study, Chest, 141, 339, 10.1378/chest.11-0340

Goette, 2016, EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication, Europace, 18, 1455, 10.1093/europace/euw161

Nattel, 2014, Early management of atrial fibrillation to prevent cardiovascular complications, Eur Heart J, 35, 1448, 10.1093/eurheartj/ehu028

Freedman, 2017, Screening for atrial fibrillation: a report of the AF-SCREEN International Collaboration, Circulation, 135, 1851, 10.1161/CIRCULATIONAHA.116.026693

Mairesse, 2017, Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE, Europace, 19, 1589, 10.1093/europace/eux177

Padfield, 2017, Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation, Heart Rhythm, 14, 801, 10.1016/j.hrthm.2017.01.038

Vidal-Perez, 2013, The change in the atrial fibrillation type as a prognosis marker in a community study: long-term data from AFBAR (Atrial Fibrillation in the BARbanza) study, Int J Cardiol, 168, 2146, 10.1016/j.ijcard.2013.01.261

de Vos, 2010, Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis, J Am Coll Cardiol, 55, 725, 10.1016/j.jacc.2009.11.040

Hobbelt, 2017, Prethrombotic state in young very low-risk patients with atrial fibrillation, J Am Coll Cardiol, 69, 1990, 10.1016/j.jacc.2017.01.057

Habibi, 2016, Cardiac magnetic resonance-measured left atrial volume and function and incident atrial fibrillation: results from MESA (Multi-Ethnic Study of Atherosclerosis), Circ Cardiovasc Imaging, 9, e004299, 10.1161/CIRCIMAGING.115.004299

Brambatti, 2014, Temporal relationship between subclinical atrial fibrillation and embolic events, Circulation, 129, 2094, 10.1161/CIRCULATIONAHA.113.007825

Guichard, 2017, Atrial Cardiomyopathy: A useful notion in cardiac disease management or a passing fad?, J Am Coll Cardiol, 70, 756, 10.1016/j.jacc.2017.06.033

Hirsh, 2015, Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences, J Am Coll Cardiol, 65, 2239, 10.1016/j.jacc.2015.03.557

Freedman, 2016, Stroke prevention in atrial fibrillation, Lancet, 388, 806, 10.1016/S0140-6736(16)31257-0

Martinez, 2014, Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study, Thromb Haemost, 112, 276, 10.1160/TH4-04-0383

Wilson, 1968, [Principles and practice of mass screening for disease], Bol Oficina Sanit Panam, 65, 281

Welton, 2017, Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis, Health Technol Assess, 21, 1, 10.3310/hta21290

Steinhubl, 2018, Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial, JAMA, 320, 146, 10.1001/jama.2018.8102

Schnabel, 2019, Searching for atrial fibrillation poststroke: a white paper of the AF-SCREEN International Collaboration, Circulation, 140, 1834, 10.1161/CIRCULATIONAHA.119.040267

Yan, 2018, Contact-free screening of atrial fibrillation by a smartphone using facial pulsatile photoplethysmographic signals, J Am Heart Assoc, 7, 10.1161/JAHA.118.008585

Orchard, 2016, Screening for atrial fibrillation during influenza vaccinations by primary care nurses using a smartphone electrocardiograph (iECG): a feasibility study, Eur J Prev Cardiol, 23, 13, 10.1177/2047487316670255

Lampert, 2018, Screening for atrial fibrillation using smartphone-based technology and layperson volunteers: high-tech meets community participatory research for the best of both worlds, Heart Rhythm, 15, 1312, 10.1016/j.hrthm.2018.07.005

Lahdenoja, 2018, Atrial fibrillation detection via accelerometer and gyroscope of a smartphone, IEEE J Biomed Health Inform, 22, 108, 10.1109/JBHI.2017.2688473

Freedman, 2016, Screening for atrial fibrillation using a smartphone: is there an app for that?, J Am Heart Assoc, 5, 10.1161/JAHA.116.004000

Chan, 2017, Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram, Heart, 103, 24, 10.1136/heartjnl-2016-309993

Chan, 2016, Diagnostic performance of a smartphone-based photoplethysmographic application for atrial fibrillation screening in a primary care setting, J Am Heart Assoc, 5, 10.1161/JAHA.116.003428

Brasier, 2019, Detection of atrial fibrillation with a smartphone camera: first prospective, international, two-centre, clinical validation study (DETECT AF PRO), Europace, 21, 41, 10.1093/europace/euy176

Tison, 2018, Passive detection of atrial fibrillation using a commercially available smartwatch, JAMA Cardiol, 3, 409, 10.1001/jamacardio.2018.0136

Li, 2019, The current state of mobile phone apps for monitoring heart rate, heart rate variability, and atrial fibrillation: narrative review, JMIR Mhealth Uhealth, 7, e11606, 10.2196/11606

Bumgarner, 2018, Smartwatch algorithm for automated detection of atrial fibrillation, J Am Coll Cardiol, 71, 2381, 10.1016/j.jacc.2018.03.003

Wasserlauf, 2019, Smartwatch performance for the detection and quantification of atrial fibrillation, Circ Arrhythm Electrophysiol, 12, e006834, 10.1161/CIRCEP.118.006834

Attia, 2019, Anartificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction, Lancet, 394, 861, 10.1016/S0140-6736(19)31721-0

Turakhia, 2019, Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study, Am Heart J, 207, 66, 10.1016/j.ahj.2018.09.002

Guo, 2019, Mobile photoplethysmographic technology to detect atrial fibrillation, J Am Coll Cardiol, 74, 2365, 10.1016/j.jacc.2019.08.019

Harris, 2012, How can we best detect atrial fibrillation?, J R Coll Physicians Edinb, 42 Suppl 18, 5, 10.4997/JRCPE.2012.S02.

Wiesel, 2004, The use of a modified sphygmomanometer to detect atrial fibrillation in outpatients, Pacing Clin Electrophysiol, 27, 639, 10.1111/j.1540-8159.2004.00499.x

Wiesel, 2009, Detection of atrial fibrillation using a modified microlife blood pressure monitor, Am J Hypertens, 22, 848, 10.1038/ajh.2009.98

Stergiou, 2009, Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation, J Hum Hypertens, 23, 654, 10.1038/jhh.2009.5

Willits, 2014, WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension: a, NICE Medical Technology Guidance. Appl Health Econ Health Policy, 12, 255, 10.1007/s40258-014-0096-7

Desteghe, 2017, Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting, Europace, 19, 29

Kaasenbrood, 2016, Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination, Europace, 18, 1514, 10.1093/europace/euv426

Wiesel, 2013, Screening for asymptomatic atrial fibrillation while monitoring the blood pressure at home: trial of regular versus irregular pulse for prevention of stroke (TRIPPS 2.0), Am J Cardiol, 111, 1598, 10.1016/j.amjcard.2013.01.331

Jacobs, 2018, Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands, Europace, 20, 12

Lowres, 2014, Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study, Thromb Haemost, 111, 1167, 10.1160/TH14-03-0231

William, 2018, Assessing the accuracy of an automated atrial fibrillation detection algorithm using smartphone technology: the iREAD Study, Heart Rhythm, 15, 1561, 10.1016/j.hrthm.2018.06.037

Nemati, 2016, Monitoring and detecting atrial fibrillation using wearable technology, Conf Proc IEEE Eng Med Biol Soc, 2016, 3394

Petryszyn, 2019, Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis, PLoS One, 14, e0213198, 10.1371/journal.pone.0213198

Orchard, 2018, Atrial fibrillation: is there enough evidence to recommend opportunistic or systematic screening?, Int J Epidemiol, 47, 1361, 10.1093/ije/dyy156

Svennberg, 2015, Mass screening for untreated atrial fibrillation: the STROKESTOP Study, Circulation, 131, 2176, 10.1161/CIRCULATIONAHA.114.014343

Halcox, 2017, Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF Study, Circulation, 136, 1784, 10.1161/CIRCULATIONAHA.117.030583

Turakhia, 2015, Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States, Am J Cardiol, 116, 733, 10.1016/j.amjcard.2015.05.045

Fay, 2017, Screening of older patients for atrial fibrillation in general practice: current evidence and its implications for future practice, Eur J Gen Pract, 23, 246, 10.1080/13814788.2017.1374366

Boriani, 2015, Asymptomatic lone atrial fibrillation – how can we detect the arrhythmia?, Curr Pharm Des, 21, 659, 10.2174/1381612820666140825142639

Hobbs, 2005, A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study, Health Technol Assess, 9, 1, 10.3310/hta9400

Aronsson, 2015, Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording, Europace, 17, 1023, 10.1093/europace/euv083

Lowres, 2013, Screening to identify unknown atrial fibrillation. A systematic review, Thromb Haemost, 110, 213, 10.1160/TH13-02-0165

Engdahl, 2013, Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention, Circulation, 127, 930, 10.1161/CIRCULATIONAHA.112.126656

Boriani, 2014, Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices), Eur Heart J, 35, 508, 10.1093/eurheartj/eht491

Lowres, 2015, Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation, Int J Clin Pharm, 37, 1111, 10.1007/s11096-015-0169-1

Wynn, 2014, The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification, Europace, 16, 965, 10.1093/europace/eut395

De With, 2019, Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study, Europace, 21, 563, 10.1093/europace/euy311

Schnabel, 2018, Symptom burden of atrial fibrillation and its relation to interventions and outcome in Europe, J Am Heart Assoc, 7, 10.1161/JAHA.117.007559

Björkenheim, 2017, Assessment of atrial fibrillation – specific symptoms before and 2 years after atrial fibrillation ablation: do patients and physicians differ in their perception of symptom relief?, JACC: Clinical Electrophysiology, 3, 1168

Sandhu, 2017, Impact of electrical cardioversion on quality of life for the treatment of atrial fibrillation, Can J Cardiol, 33, 450, 10.1016/j.cjca.2016.11.013

Singh, 2005, Amiodarone versus sotalol for atrial fibrillation, N Engl J Med, 352, 1861, 10.1056/NEJMoa041705

Gilbert, 2015, Restoration of sinus rhythm results in early and late improvements in the functional reserve of the heart following direct current cardioversion of persistent AF: FRESH-AF, Int J Cardiol, 199, 121, 10.1016/j.ijcard.2015.07.020

Jais, 2008, Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study, Circulation, 118, 2498, 10.1161/CIRCULATIONAHA.108.772582

Oral, 2006, Circumferential pulmonary-vein ablation for chronic atrial fibrillation, N Engl J Med, 354, 934, 10.1056/NEJMoa050955

Mont, 2014, Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study, Eur Heart J, 35, 501, 10.1093/eurheartj/eht457

Forleo, 2009, Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy, J Cardiovasc Electrophysiol, 20, 22, 10.1111/j.1540-8167.2008.01275.x

Wilber, 2010, Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial, JAMA, 303, 333, 10.1001/jama.2009.2029

Wazni, 2005, Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial, JAMA, 293, 2634, 10.1001/jama.293.21.2634

Morillo, 2014, Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial, JAMA, 311, 692, 10.1001/jama.2014.467

Cosedis Nielsen, 2012, Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation, N Engl J Med, 367, 1587, 10.1056/NEJMoa1113566

Pokorney, 2017, Cardioversion and subsequent quality of life and natural history of atrial fibrillation, Am Heart J, 185, 59, 10.1016/j.ahj.2016.10.018

Mantovan, 2013, Relationship of quality of life with procedural success of atrial fibrillation (AF) ablation and postablation AF burden: substudy of the STAR AF randomized trial, Can J Cardiol, 29, 1211, 10.1016/j.cjca.2013.06.006

Rienstra, 2018, Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial, Eur Heart J, 39, 2987, 10.1093/eurheartj/ehx739

Blomstrom-Lundqvist, 2019, Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial, JAMA, 321, 1059, 10.1001/jama.2019.0335

Mark, 2019, Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 10.1001/jama.2019.0692

Gaita, 2018, Very long-term outcome following transcatheter ablation of atrial fibrillation. Are results maintained after 10 years of follow-up?, Europace, 20, 443, 10.1093/europace/eux008

Donal, 2016, EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation, Eur Heart J Cardiovasc Imaging, 17, 355, 10.1093/ehjci/jev354

Delgado, 2017, Structure and function of the left atrium and left atrial appendage: AF and stroke implications, J Am Coll Cardiol, 70, 3157, 10.1016/j.jacc.2017.10.063

Oakes, 2009, Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation, Circulation, 119, 1758, 10.1161/CIRCULATIONAHA.108.811877

Cameli, 2013, Usefulness of atrial deformation analysis to predict left atrial fibrosis and endocardial thickness in patients undergoing mitral valve operations for severe mitral regurgitation secondary to mitral valve prolapse, Am J Cardiol, 111, 595, 10.1016/j.amjcard.2012.10.049

Nakamori, 2018, Left atrial epicardial fat volume is associated with atrial fibrillation: a prospective cardiovascular magnetic resonance 3D Dixon Study, J Am Heart Assoc, 7, 10.1161/JAHA.117.008232

Murphy, 2017, The World Heart Federation roadmap for nonvalvular atrial fibrillation, Glob Heart, 12, 273, 10.1016/j.gheart.2017.01.015

Timmis, 2020, European Society of Cardiology: Cardiovascular Disease Statistics 2019, Eur Heart J, 41, 12, 10.1093/eurheartj/ehz859

Charles, 1999, What do we mean by partnership in making decisions about treatment?, BMJ, 319, 780, 10.1136/bmj.319.7212.780

Lane, 2015, Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE), Europace, 17, 1747, 10.1093/europace/euv233

Bergtun, 2019, Patients’ experiences 1-6 months after atrial fibrillation ablation: an holistic perspective, J Adv Nurs, 75, 150, 10.1111/jan.13843

Borg Xuereb, 2016, Patients’ and physicians’ experiences of atrial fibrillation consultations and anticoagulation decision-making: a multi-perspective IPA design, Psychol Health, 31, 436, 10.1080/08870446.2015.1116534

Loewen, 2017, Patient values and preferences for antithrombotic therapy in atrial fibrillation. A narrative systematic review, Thromb Haemost, 117, 1007, 10.1160/TH16-10-0787

Seaburg, 2014, Shared decision making in atrial fibrillation: where we are and where we should be going, Circulation, 129, 704, 10.1161/CIRCULATIONAHA.113.004498

Bajorek, 2007, Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers, Med J Aust, 186, 175, 10.5694/j.1326-5377.2007.tb00856.x

Hess, 2012, The chest pain choice decision aid: a randomized trial, Circ Cardiovasc Qual Outcomes, 5, 251, 10.1161/CIRCOUTCOMES.111.964791

Lane, 2018, Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: results of a conjoint analysis, Clin Cardiol, 41, 855, 10.1002/clc.22971

Lindberg, 2017, Older individuals’ need for knowledge and follow-up about their chronic atrial fibrillation, lifelong medical treatment and medical controls, Scand J Caring Sci, 31, 1022, 10.1111/scs.12427

Palacio, 2015, Patient values and preferences when choosing anticoagulants, Patient Prefer Adherence, 9, 133

Lane, 2014, Patient’s values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation, Thromb Haemost, 111, 381, 10.1160/TH14-01-0063

MacLean, 2012, Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, e1S, 10.1378/chest.11-2290

Desteghe, 2016, Knowledge gaps in patients with atrial fibrillation revealed by a new validated knowledge questionnaire, Int J Cardiol, 223, 906, 10.1016/j.ijcard.2016.08.303

Frankel, 2015, HRS/NSA 2014 Survey of atrial fibrillation and stroke: gaps in knowledge and perspective, opportunities for improvement, J Stroke Cerebrovasc Dis, 24, 1691, 10.1016/j.jstrokecerebrovasdis.2015.06.026

Lane, 2006, Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project, Int J Cardiol, 110, 354, 10.1016/j.ijcard.2005.07.031

McCabe, 2008, Knowledge and self-management behaviors of patients with recently detected atrial fibrillation, Heart Lung, 37, 79, 10.1016/j.hrtlng.2007.02.006

Ihara, 2018, Linking atrial fibrillation with Alzheimer’s disease: epidemiological, pathological, and mechanistic evidence, J Alzheimers Dis, 62, 61, 10.3233/JAD-170970

Lip, 2017, Streamlining primary and secondary care management pathways for stroke prevention in atrial fibrillation, Eur Heart J, 38, 2980, 10.1093/eurheartj/ehx554

Guo, 2019, Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: the mAFA (mAF-App) II randomised trial, Int J Clin Pract, e13352

Franchi, 2019, Simulation-based education for physicians to increase oral anticoagulants in hospitalized elderly patients with atrial fibrillation, Am J Med, 10.1016/j.amjmed.2019.03.052

Vinereanu, 2017, A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial, Lancet, 390, 1737, 10.1016/S0140-6736(17)32165-7

Raparelli, 2017, Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants, Thromb Haemost, 117, 209, 10.1160/TH16-10-0757

Parimbelli, 2016, The role of nurses in e-health: the MobiGuide project experience, Stud Health Technol Inform, 225, 153

Guo, 2017, Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAF App trial, Am J Med, 130, 1388, 10.1016/j.amjmed.2017.07.003

Kotecha, 2018, European Society of Cardiology (ESC) Atrial Fibrillation Guidelines Taskforce, the CATCH ME consortium, and the European Heart Rhythm Association (EHRA). European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers, Europace, 20, 225, 10.1093/europace/eux299

Lee, 2016, Feasibility study of a mobile health intervention for older adults on oral anticoagulation therapy, Gerontol Geriatr Med, 2, 10.1177/2333721416672970

Stephan, 2017, Processes and recommendations for creating mHealth apps for low-income populations, JMIR Mhealth Uhealth, 5, e41, 10.2196/mhealth.6510

Clarkesmith, 2017, Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation, Cochrane Database Syst Rev, 4, CD008600

Man-Son-Hing, 1999, A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial, JAMA, 282, 737, 10.1001/jama.282.8.737

McAlister, 2005, Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial, CMAJ, 173, 496, 10.1503/cmaj.050091

Thomson, 2007, A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial, Qual Saf Health Care, 16, 216, 10.1136/qshc.2006.018481

Eckman, 2018, Shared decision-making tool for thromboprophylaxis in atrial fibrillation – a feasibility study, Am Heart J, 199, 13, 10.1016/j.ahj.2018.01.003

Eckman, 2016, Impact of an atrial fibrillation decision support tool on thromboprophylaxis for atrial fibrillation, Am Heart J, 176, 17, 10.1016/j.ahj.2016.02.009

Karlsson, 2018, A clinical decision support tool for improving adherence to guidelines on anticoagulant therapy in patients with atrial fibrillation at risk of stroke: a cluster-randomized trial in a Swedish primary care setting (the CDS-AF study), PLoS Med, 15, e1002528, 10.1371/journal.pmed.1002528

Vinereanu, 2017, Echocardiographic risk factors for stroke and outcomes in patients with atrial fibrillation anticoagulated with apixaban or warfarin, Stroke, 48, 3266, 10.1161/STROKEAHA.117.017574

Hendriks, 2012, Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation, Eur Heart J, 33, 2692, 10.1093/eurheartj/ehs071

Stewart, 2015, Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial, Lancet, 385, 775, 10.1016/S0140-6736(14)61992-9

Carter, 2016, An integrated management approach to atrial fibrillation, J Am Heart Assoc, 5, 10.1161/JAHA.115.002950

Wijtvliet, 2020, Nurse-led vs. usual-care for atrial fibrillation, Eur Heart J, 41, 634, 10.1093/eurheartj/ehz666

Gallagher, 2017, Integrated care in atrial fibrillation: a systematic review and meta-analysis, Heart, 103, 1947

Michie, 2011, The behaviour change wheel: a new method for characterising and designing behaviour change interventions, Implement Sci, 6

Lip, 2018, Innovative strategies to improve adherence to non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation, Eur Heart J, 39, 1404, 10.1093/eurheartj/ehx807

Seligman, 2020, Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group, Eur Heart J, 10.1093/eurheartj/ehz871

Dobler, 2018, Treatment burden should be included in clinical practice guidelines, BMJ, 363, k4065, 10.1136/bmj.k4065

Eton, 2012, Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study, Patient Relat Outcome Meas, 3, 39, 10.2147/PROM.S34681

Tran, 2012, Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions, BMC Med, 10, 68, 10.1186/1741-7015-10-68

Vijan, 2005, Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens, J Gen Intern Med, 20, 479, 10.1111/j.1525-1497.2005.0117.x

Vermeire, 2001, Patient adherence to treatment: three decades of research. A comprehensive review, J Clin Pharm Ther, 26, 331, 10.1046/j.1365-2710.2001.00363.x

Ho, 2006, Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus, Arch Intern Med, 166, 1836, 10.1001/archinte.166.17.1836

Rasmussen, 2007, Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction, JAMA, 297, 177, 10.1001/jama.297.2.177

May, 2009, We need minimally disruptive medicine, BMJ, 339, b2803, 10.1136/bmj.b2803

Wilcox, 2010, A new tool to measure the burden of Crohn’s disease and its treatment: do patient and physician perceptions match?, Inflamm Bowel Dis, 16, 645, 10.1002/ibd.21094

Bohlen, 2012, Overwhelmed patients: a videographic analysis of how patients with type 2 diabetes and clinicians articulate and address treatment burden during clinical encounters, Diabetes Care, 35, 47, 10.2337/dc11-1082

Buffel du Vaure, 2016, Potential workload in applying clinical practice guidelines for patients with chronic conditions and multimorbidity: a systematic analysis, BMJ Open, 6, e010119, 10.1136/bmjopen-2015-010119

Potpara, 2020, Self-reported treatment burden in patients with atrial fibrillation: quantification, major determinants and implications for integrated holistic management of the arrhythmia, Europace, 10.1093/europace/euaa210

Tran, 2014, Adaptation and validation of the Treatment Burden Questionnaire (TBQ) in English using an internet platform, BMC Med, 12, 109, 10.1186/1741-7015-12-109

Steinberg, 2019, Patient-reported outcomes in atrial fibrillation research: results of a Clinicaltrials.gov analysis, JACC Clin Electrophysiol, 5, 599, 10.1016/j.jacep.2019.03.008

Calvert, 2019, Maximising the impact of patient reported outcome assessment for patients and society, BMJ, 364, k5267, 10.1136/bmj.k5267

Rotenstein, 2017, Making patients and doctors happier – the potential of patient-reported outcomes, N Engl J Med, 377, 1309, 10.1056/NEJMp1707537

Van Der Wees, 2014, Integrating the use of patient-reported outcomes for both clinical practice and performance measurement: views of experts from 3 countries, Milbank Q, 92, 754, 10.1111/1468-0009.12091

Arbelo, 2020, Quality indicators for the care and outcomes of adults with atrial fibrillation. Task Force for the development of quality indicators in Atrial Fibrillation of the European Heart Rhythm Association (EHRA) and of the European Society of Cardiology (ESC): Developed in collaboration with the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS) and the Latin-American Heart Rhythm Society (LAHRS), Europace

Lip, 2017, The ABC pathway: an integrated approach to improve AF management, Nat Rev Cardiol, 14, 627, 10.1038/nrcardio.2017.153

Proietti, 2018, Improved outcomes by integrated care of anticoagulated patients with atrial fibrillation using the simple ABC (Atrial Fibrillation Better Care) Pathway, Am J Med, 131, 1359, 10.1016/j.amjmed.2018.06.012

Yoon, 2019, Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) pathway for integrated care management: a nationwide cohort study, Thromb Haemost, 19, 1695, 10.1055/s-0039-1693516

Pastori, Integrated care management of patients with atrial fibrillation and risk of cardiovascular events: the ABC (Atrial fibrillation Better Care) pathway in the ATHERO-AF study cohort, Mayo Clin Proc

Pastori, 2019, ABC (Atrial fibrillation Better Care) pathway and healthcare costs in atrial fibrillation: the ATHERO-AF study, Am J Med, 10.1016/j.amjmed.2019.01.003

Guo, 2020, Lip GYH; mAF-App II Trial Investigators. Mobile health technology to improve care for patients with atrial fibrillation, J Am Coll Cardiol, 75, 1523, 10.1016/j.jacc.2020.01.052

Pisters, 2012, Stroke and thromboembolism in atrial fibrillation, Circ J, 76, 2289, 10.1253/circj.CJ-12-1036

Szymanski, 2015, Stroke risk factors beyond the CHA(2)DS(2)-VASc score: can we improve our identification of ‘high stroke risk’ patients with atrial fibrillation?, Am J Cardiol, 116, 1781, 10.1016/j.amjcard.2015.08.049

1998, Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials, Arch Intern Med, 158, 1316, 10.1001/archinte.158.12.1316

Ntaios, 2015, Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation, Neurology, 84, 1213, 10.1212/WNL.0000000000001402

Esteve-Pastor, 2019, The use of biomarkers in clinical management guidelines: a critical appraisal, Thromb Haemost, 119, 1901, 10.1055/s-0039-1696955

Hijazi, 2017, Application of biomarkers for risk stratification in patients with atrial fibrillation, Clin Chem, 63, 152, 10.1373/clinchem.2016.255182

Yaghi, 2017, Stratifying stroke risk in atrial fibrillation: beyond clinical risk scores, Stroke, 48, 2665, 10.1161/STROKEAHA.117.017084

Ioannou, 2019, Biomarkers associated with stroke risk in atrial fibrillation, Curr Med Chem, 26, 803, 10.2174/0929867324666170718120651

Sepehri Shamloo, 2020, Natriuretic peptides: biomarkers for atrial fibrillation management, Clin Res Cardiol, 10.1007/s00392-020-01608-x

Decker, 2019, Metabolic syndrome and risk of ischemic stroke in atrial fibrillation: ARIC Study, Stroke, 50, 3045, 10.1161/STROKEAHA.119.025376

Lip, 2010, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation, Chest, 137, 263, 10.1378/chest.09-1584

Banerjee, 2012, Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project, Eur J Heart Fail, 14, 295, 10.1093/eurjhf/hfs005

Jung, 2018, Stroke risk stratification for atrial fibrillation patients with hypertrophic cardiomyopathy, J Am Coll Cardiol, 72, 2409, 10.1016/j.jacc.2018.07.098

Jung, 2019, Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study, Chest, 155, 354, 10.1016/j.chest.2018.11.009

Kim, 2018, Ideal blood pressure in patients with atrial fibrillation, J Am Coll Cardiol, 72, 1233, 10.1016/j.jacc.2018.05.076

Lip, 2015, Stroke and major bleeding risk in elderly patients aged >/=75 years with atrial fibrillation: the Loire Valley Atrial Fibrillation Project, Stroke, 46, 143, 10.1161/STROKEAHA.114.007199

Overvad, 2015, Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study, Stroke, 46, 2168, 10.1161/STROKEAHA.115.009371

Lip, 2015, The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project, Chest, 147, 1103, 10.1378/chest.14-2096

Fangel, 2018, Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: a Danish nationwide cohort study, Int J Cardiol, 268, 137, 10.1016/j.ijcard.2018.05.037

Chao, 2016, Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage, Circulation, 133, 1540, 10.1161/CIRCULATIONAHA.115.019794

Bronnum Nielsen, 2015, Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study, Chest, 147, 1651, 10.1378/chest.14-2099

Nielsen, 2015, Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study, Circulation, 132, 517, 10.1161/CIRCULATIONAHA.115.015735

Lin, 2011, Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation – a nation-wide database analysis, Atherosclerosis, 217, 292, 10.1016/j.atherosclerosis.2011.03.033

Anandasundaram, 2013, The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review, J Thromb Haemost, 11, 975, 10.1111/jth.12177

Friberg, 2012, Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study, Eur Heart J, 33, 1500, 10.1093/eurheartj/ehr488

Steensig, 2018, Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the Western Denmark Heart Registry, Thromb Haemost, 118, 2162, 10.1055/s-0038-1675401

Zabalgoitia, 1998, Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation, J Am Coll Cardiol, 31, 1622, 10.1016/S0735-1097(98)00146-6

Kim, 2018, Age threshold for ischemic stroke risk in atrial fibrillation, Stroke, 49, 1872, 10.1161/STROKEAHA.118.021047

Chao, 2015, Age threshold for increased stroke risk among patients with atrial fibrillation: a nationwide cohort study from Taiwan, J Am Coll Cardiol, 66, 1339, 10.1016/j.jacc.2015.07.026

Nielsen, 2018, Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?, Circulation, 137, 832, 10.1161/CIRCULATIONAHA.117.029081

Killu, 2019, Risk stratification for stroke in atrial fibrillation: a critique, Eur Heart J, 40, 1294, 10.1093/eurheartj/ehy731

Rivera-Caravaca, 2017, Long-term stroke risk prediction in patients with atrial fibrillation: comparison of the ABC-Stroke and CHA2DS2-VASc scores, J Am Heart Assoc, 6, 10.1161/JAHA.117.006490

Alkhouli, 2019, Ischemic stroke risk in patients with nonvalvular atrial fibrillation: JACC review topic of the week, J Am Coll Cardiol, 74, 3050, 10.1016/j.jacc.2019.10.040

Wu, 2020, Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation, Heart, 10.1136/heartjnl-2019-315065

Tomasdottir, 2019, Risk of ischemic stroke and utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation, Clin Cardiol, 42, 1003, 10.1002/clc.23257

Friberg, 2012, Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study, BMJ, 344, e3522, 10.1136/bmj.e3522

Overvad, 2019, Stroke risk stratification: CHA2DS2-VA or CHA2DS2-VASc?, Heart Lung Circ, 28, e14, 10.1016/j.hlc.2018.08.012

Nielsen, 2020, Female sex as a risk modifier for stroke risk in atrial fibrillation: using CHA2DS2-VASc versus CHA2DS2-VA for stroke risk stratification in atrial fibrillation: a note of caution, Thromb Haemost

Marzona, 2018, Sex differences in stroke and major adverse clinical events in patients with atrial fibrillation: a systematic review and meta-analysis of 993,600 patients, Int J Cardiol, 269, 182, 10.1016/j.ijcard.2018.07.044

Friberg, 2015, Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study, Eur Heart J, 36, 297, 10.1093/eurheartj/ehu139

Poli, 2017, Atrial fibrillation is a major cause of stroke in apneic patients: a prospective study, Sleep Med, 30, 251, 10.1016/j.sleep.2015.07.031

Bassand, 2018, Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: rationale for comprehensive management of atrial fibrillation, PLoS One, 13, e0191592, 10.1371/journal.pone.0191592

Overvad, 2013, Body mass index and adverse events in patients with incident atrial fibrillation, Am J Med, 126, 640.e9-17, 10.1016/j.amjmed.2012.11.024

Lip, 2006, Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation, Stroke, 37, 2294, 10.1161/01.STR.0000236840.00467.84

Fox, 2017, Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation, BMJ Open, 7, e017157, 10.1136/bmjopen-2017-017157

Zhu, 2017, Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation, Int J Cardiol, 227, 436, 10.1016/j.ijcard.2016.11.015

Singer, 2013, A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score, J Am Heart Assoc, 2, e000250, 10.1161/JAHA.113.000250

Graves, 2018, Improving CHA2DS2-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation, Open Heart, 5, e000907, 10.1136/openhrt-2018-000907

Hijazi, 2016, The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation, Eur Heart J, 37, 1582, 10.1093/eurheartj/ehw054

Hijazi, 2017, Repeated measurements of cardiac biomarkers in atrial fibrillation and validation of the ABC stroke score over time, J Am Heart Assoc, 6, 10.1161/JAHA.116.004851

Oldgren, 2016, Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation, Circulation, 134, 1697, 10.1161/CIRCULATIONAHA.116.022802

Berg, 2019, Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48, Circulation, 139, 760, 10.1161/CIRCULATIONAHA.118.038312

Rivera-Caravaca, 2019, Refining stroke and bleeding prediction in atrial fibrillation by adding consecutive biomarkers to clinical risk scores, Stroke, 50, 1372, 10.1161/STROKEAHA.118.024305

Esteve-Pastor, 2017, Long-term bleeding risk prediction in ‘real world’patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores, Thromb Haemost, 117, 1848, 10.1160/TH17-07-0478

Shin, 2019, Identification of markers associated with development of stroke in ‘clinically low-risk’ atrial fibrillation patients, J Am Heart Assoc, 8, e012697, 10.1161/JAHA.119.012697

Chao, 2019, Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities, Eur Heart J, 40, 1504, 10.1093/eurheartj/ehy837

Nielsen, 2016, Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study, Sci Rep, 6, 27410, 10.1038/srep27410

Fauchier, 2016, Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated?, Stroke, 47, 1831, 10.1161/STROKEAHA.116.013253

Chao, 2018, Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation, J Am Coll Cardiol, 71, 122, 10.1016/j.jacc.2017.10.085

Yoon, 2018, Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in Asian patients with atrial fibrillation: a nationwide cohort study, Thromb Haemost, 118, 1296, 10.1055/s-0038-1651482

Chao, 2019, Reassessment of risk for stroke during follow-up of patients with atrial fibrillation, Ann Intern Med, 170, 663, 10.7326/M18-1177

Potpara, 2012, Reliable identification of ‘truly low’ thromboembolic risk in patients initially diagnosed with ‘lone’ atrial fibrillation: the Belgrade Atrial Fibrillation Study, Circ Arrhythm Electrophysiol, 5, 319, 10.1161/CIRCEP.111.966713

Weijs, 2019, Idiopathic atrial fibrillation patients rapidly outgrow their low thromboembolic risk: a 10-year follow-up study, Neth Heart J, 27, 487, 10.1007/s12471-019-1272-z

Chao, 2019, Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially ‘low-risk’ patients, Thromb Haemost, 119, 1162, 10.1055/s-0039-1683933

Borre, 2018, Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review, Thromb Haemost, 118, 2171, 10.1055/s-0038-1675400

Chao, 2018, Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and Delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors, Thromb Haemost, 118, 768, 10.1055/s-0038-1636534

Man-Son-Hing, 1999, Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls, Arch Intern Med, 159, 677, 10.1001/archinte.159.7.677

Gage, 2006, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF), Am Heart J, 151, 713, 10.1016/j.ahj.2005.04.017

Fang, 2011, A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study, J Am Coll Cardiol, 58, 395, 10.1016/j.jacc.2011.03.031

O'Brien, 2015, The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation, Eur Heart J, 36, 3258

Rohla, 2019, Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events – European Registry in Atrial Fibrillation (PREFER in AF, BMJ Open, 9, e022478, 10.1136/bmjopen-2018-022478

Pisters, 2010, A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, 138, 1093, 10.1378/chest.10-0134

Mori, 2019, External validation of the ORBIT bleeding score and the HAS-BLED score in nonvalvular atrial fibrillation patients using direct oral anticoagulants (Asian data from the DIRECT registry), Am J Cardiol, 124, 1044, 10.1016/j.amjcard.2019.07.005

Yao, 2017, Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation, Am J Cardiol, 120, 1549, 10.1016/j.amjcard.2017.07.051

Rutherford, 2018, New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs, Open Heart, 5, e000931, 10.1136/openhrt-2018-000931

Thomas, 2017, Novel risk markers and risk assessments for cardiovascular disease, Circ Res, 120, 133, 10.1161/CIRCRESAHA.116.309955

Khan, 2019, The prothrombotic state in atrial fibrillation: pathophysiological and management implications, Cardiovasc Res, 115, 31, 10.1093/cvr/cvy272

Ban, 2017, GDF15 is elevated in mice following retinal ganglion cell death and in glaucoma patients, JCI Insight, 2, 10.1172/jci.insight.91455

Hijazi, 2016, The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study, Lancet, 387, 2302, 10.1016/S0140-6736(16)00741-8

Esteve-Pastor, 2017, Long-term bleeding risk prediction in ‘real world’ patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project, Thromb Haemost, 117, 1848, 10.1160/TH17-07-0478

Caldeira, 2014, Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis, J Interv Card Electrophysiol, 40, 277, 10.1007/s10840-014-9930-y

Zhu, 2015, The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis, Clin Cardiol, 38, 555, 10.1002/clc.22435

Chang, 2020, Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: a network meta-analysis, J Thromb Haemost, 10.1111/jth.14692

Lip, 2016, Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores, J Thromb Haemost, 14, 1711, 10.1111/jth.13386

Chao, 2018, Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study, Int J Cardiol, 254, 157, 10.1016/j.ijcard.2017.11.025

Guo, 2018, Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation, Am J Med, 131, 185, 10.1016/j.amjmed.2017.09.009

Esteve-Pastor, 2017, Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial, Thromb Haemost, 117, 2261, 10.1160/TH17-10-0710

Guo, 2020, Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial, Am J Med, 10.1016/j.amjmed.2020.03.019

Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007

De Caterina, 2013, Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC working group on thrombosis – Task Force on anticoagulants in heart disease, Thromb Haemost, 110, 1087, 10.1160/TH13-06-0443

Wan, 2008, Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review, Circ Cardiovasc Qual Outcomes, 1, 84, 10.1161/CIRCOUTCOMES.108.796185

Sjalander, 2018, Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation, Thromb Res, 167, 113, 10.1016/j.thromres.2018.05.022

Amin, 2014, Estimation of the impact of warfarin’s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials, J Thromb Thrombolysis, 38, 150, 10.1007/s11239-013-1048-z

Apostolakis, 2013, Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score, Chest, 144, 1555, 10.1378/chest.13-0054

Proietti, 2015, Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score, Eur Heart J Cardiovasc Pharmacother, 1, 150, 10.1093/ehjcvp/pvv012

Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561

Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638

Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039

Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907

Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0

Wang, 2015, Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis, Stroke, 46, 2555, 10.1161/STROKEAHA.115.009947

Connolly, 2011, Apixaban in patients with atrial fibrillation, N Engl J Med, 364, 806, 10.1056/NEJMoa1007432

Carmo, 2016, Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists, Thromb Haemost, 116, 754, 10.1160/TH16-03-0203

Huisman, 2018, Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry, Am Heart J, 198, 55, 10.1016/j.ahj.2017.08.018

Camm, 2016, XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation, Eur Heart J, 37, 1145, 10.1093/eurheartj/ehv466

Martinez, 2018, XANTUS-EL: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America, Egypt Heart J, 70, 307, 10.1016/j.ehj.2018.09.002

Li, 2017, Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in ‘real-world’ clinical practice. A propensity-matched analysis of 76,940 patients, Thromb Haemost, 117, 1072, 10.1160/TH17-01-0068

Lee, 2018, Edoxaban in Asian patients with atrial fibrillation: effectiveness and safety, J Am Coll Cardiol, 72, 838, 10.1016/j.jacc.2018.05.066

Ingrasciotta, 2018, Pharmacokinetics of new oral anticoagulants: implications for use in routine care, Expert Opin Drug Metab Toxicol, 14, 1057, 10.1080/17425255.2018.1530213

Chao, 2018, Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study, Circulation, 138, 37, 10.1161/CIRCULATIONAHA.117.031658

Stanton, 2017, Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment, Pharmacotherapy, 37, 412, 10.1002/phar.1905

Siontis, 2018, Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States, Circulation, 138, 1519, 10.1161/CIRCULATIONAHA.118.035418

Steinberg, 2016, Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry, J Am Coll Cardiol, 68, 2597, 10.1016/j.jacc.2016.09.966

Yao, 2017, Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction, J Am Coll Cardiol, 69, 2779, 10.1016/j.jacc.2017.03.600

Connolly, 2006, Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet, 367, 1903, 10.1016/S0140-6736(06)68845-4

Connolly, 2009, Effect of clopidogrel added to aspirin in patients with atrial fibrillation, N Engl J Med, 360, 2066, 10.1056/NEJMoa0901301

Sjalander, 2014, Atrial fibrillation patients do not benefit from acetylsalicylic acid, Europace, 16, 631, 10.1093/europace/eut333

Mant, 2007, Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, Lancet, 370, 493, 10.1016/S0140-6736(07)61233-1

Lip, 2011, The role of aspirin for stroke prevention in atrial fibrillation, Nat Rev Cardiol, 8, 602, 10.1038/nrcardio.2011.112

Verheugt, 2018, Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry, Eur Heart J, 39, 464, 10.1093/eurheartj/ehx730

Holmes, 2009, Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial, Lancet, 374, 534, 10.1016/S0140-6736(09)61343-X

Reddy, 2013, Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial, Circulation, 127, 720, 10.1161/CIRCULATIONAHA.112.114389

Holmes, 2014, Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial, J Am Coll Cardiol, 64, 1, 10.1016/j.jacc.2014.04.029

Holmes, 2015, Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis, J Am Coll Cardiol, 65, 2614, 10.1016/j.jacc.2015.04.025

Reddy, 2013, Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology), J Am Coll Cardiol, 61, 2551, 10.1016/j.jacc.2013.03.035

Boersma, 2016, Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry, Eur Heart J, 37, 2465, 10.1093/eurheartj/ehv730

Boersma, 2017, Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial, Heart Rhythm, 14, 1302, 10.1016/j.hrthm.2017.05.038

Badheka, 2015, Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: influence of hospital, Circ Arrhythm Electrophysiol, 8, 42, 10.1161/CIRCEP.114.001413

Pison, 2015, Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey, Europace, 17, 642, 10.1093/europace/euv069

Price, 2014, Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the US transcatheter LAA ligation consortium, J Am Coll Cardiol, 64, 565, 10.1016/j.jacc.2014.03.057

Fauchier, 2018, Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation, J Am Coll Cardiol, 71, 1528, 10.1016/j.jacc.2018.01.076

Lakkireddy, 2016, Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation, Heart Rhythm, 13, 1030, 10.1016/j.hrthm.2016.01.022

van Laar, 2018, Thoracoscopic left atrial appendage clipping: a multicenter cohort analysis, JACC Clin Electrophysiol, 4, 893, 10.1016/j.jacep.2018.03.009

Healey, 2005, Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke, Am Heart J, 150, 288, 10.1016/j.ahj.2004.09.054

Whitlock, 2013, Left Atrial Appendage Occlusion Study II (LAAOS II), Can J Cardiol, 29, 1443, 10.1016/j.cjca.2013.06.015

Tsai, 2015, Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis, Eur J Cardiothorac Surg, 47, 847, 10.1093/ejcts/ezu291

Aryana, 2015, Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization, Heart Rhythm, 12, 1431, 10.1016/j.hrthm.2015.03.028

Gillinov, 2015, Surgical ablation of atrial fibrillation during mitral-valve surgery, N Engl J Med, 372, 1399, 10.1056/NEJMoa1500528

Whitlock, 2014, Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III, Ann Cardiothorac Surg, 3, 45

Nielsen, 2017, Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study, BMJ, 356, j510, 10.1136/bmj.j510

Larsen, 2016, Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study, BMJ, 353, i3189, 10.1136/bmj.i3189

Tilz, 2017, Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey, Europace, 19, 1737, 10.1093/europace/eux254

Ogawa, 2018, Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events, Stroke, 49, 2301, 10.1161/STROKEAHA.118.021396

Mahajan, 2018, Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis, Eur Heart J, 39, 1407, 10.1093/eurheartj/ehx731

Van Gelder, 2017, Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT, Eur Heart J, 38, 1339, 10.1093/eurheartj/ehx042

Boriani, 2018, Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden, Heart Rhythm, 15, 376, 10.1016/j.hrthm.2017.11.007

Pastori, 2018, Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants, Int J Cardiol, 264, 58, 10.1016/j.ijcard.2018.01.097

Kuo, 2017, Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention?, J Am Heart Assoc, 6, 10.1161/JAHA.116.005307

Lee, 2019, Direct oral anticoagulants in patients with atrial fibrillation and liver disease, J Am Coll Cardiol, 73, 3295, 10.1016/j.jacc.2019.04.052

Staerk, 2015, Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study, BMJ, 351, h5876, 10.1136/bmj.h5876

Eckman, 2011, Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation, Circ Cardiovasc Qual Outcomes, 4, 14, 10.1161/CIRCOUTCOMES.110.958108

Proietti, 2016, Major outcomes in atrial fibrillation patients with one risk factor: impact of time in therapeutic range observations from the SPORTIF trials, Am J Med, 129, 1110, 10.1016/j.amjmed.2016.03.024

Lip, 2016, Should patients with atrial fibrillation and 1 stroke risk factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) be anticoagulated? Yes: even 1 stroke risk factor confers a real risk of stroke, Circulation, 133, 1498, 10.1161/CIRCULATIONAHA.115.016713

Lip, 2015, Stroke prevention in atrial fibrillation: a systematic review, JAMA, 313, 1950, 10.1001/jama.2015.4369

Hijazi, 2016, Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: insights from the ARISTOTLE randomized clinical trial, JAMA Cardiol, 1, 451, 10.1001/jamacardio.2016.1170

Bohm, 2015, Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial, J Am Coll Cardiol, 65, 2481, 10.1016/j.jacc.2015.03.577

Clarkesmith, 2013, Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial, PLoS One, 8, e74037, 10.1371/journal.pone.0074037

Teiger, 2018, Percutaneous left atrial appendage closure is a reasonable option for patients with atrial fibrillation at high risk for cerebrovascular events, Circ Cardiovasc Interv, 11, 005841, 10.1161/CIRCINTERVENTIONS.117.005841

Saw, 2017, Early Canadian multicenter experience with WATCHMAN for percutaneous left atrial appendage closure, J Cardiovasc Electrophysiol, 28, 396, 10.1111/jce.13168

Martin Gutierrez, 2020, Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients, Eur J Cardiothorac Surg, 57, 252

Al-Khatib, 2014, Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review, Ann Intern Med, 160, 760, 10.7326/M13-1467

Tamariz, 2004, Pharmacological rate control of atrial fibrillation, Cardiol Clin, 22, 35, 10.1016/S0733-8651(03)00111-5

Nikolaidou, 2009, Chronic atrial fibrillation: a systematic review of medical heart rate control management, Postgrad Med J, 85, 303, 10.1136/pgmj.2008.068908

Groenveld, 2011, The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study, J Am Coll Cardiol, 58, 1795, 10.1016/j.jacc.2011.06.055

Van Gelder, 2010, Lenient versus strict rate control in patients with atrial fibrillation, N Engl J Med, 362, 1363, 10.1056/NEJMoa1001337

Van Gelder, 2006, Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies, Europace, 8, 935, 10.1093/europace/eul106

Van Gelder, 2016, Rate control in atrial fibrillation, Lancet, 388, 818, 10.1016/S0140-6736(16)31258-2

Kotecha, 2014, Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis, Lancet, 384, 2235, 10.1016/S0140-6736(14)61373-8

Ulimoen, 2013, Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation, Am J Cardiol, 111, 225, 10.1016/j.amjcard.2012.09.020

Ulimoen, 2014, Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation, Eur Heart J, 35, 517, 10.1093/eurheartj/eht429

Figulla, 1996, Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy trial, Circulation, 94, 346, 10.1161/01.CIR.94.3.346

Hallberg, 2007, Digoxin and mortality in atrial fibrillation: a prospective cohort study, Eur J Clin Pharmacol, 63, 959, 10.1007/s00228-007-0346-9

Turakhia, 2014, Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study, J Am Coll Cardiol, 64, 660, 10.1016/j.jacc.2014.03.060

Whitbeck, 2013, Increased mortality among patients taking digoxin – analysis from the AFFIRM study, Eur Heart J, 34, 1481, 10.1093/eurheartj/ehs348

Andrey, 2011, Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study, Int J Clin Pract, 65, 1250, 10.1111/j.1742-1241.2011.02771.x

Flory, 2012, Observational cohort study of the safety of digoxin use in women with heart failure, BMJ Open, 2, e000888, 10.1136/bmjopen-2012-000888

Gheorghiade, 2013, Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial, Eur Heart J, 34, 1489, 10.1093/eurheartj/eht120

Aguirre Davila, 2019, Digoxin-mortality: randomized vs. observational comparison in the DIG trial, Eur Heart J, 40, 3336, 10.1093/eurheartj/ehz395

Ziff, 2015, Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data, BMJ, 351, h4451, 10.1136/bmj.h4451

Bavendiek, 2019, Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study, Eur J Heart Fail, 21, 676, 10.1002/ejhf.1452

Clemo, 1998, Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias, Am J Cardiol, 81, 594, 10.1016/S0002-9149(97)00962-4

Klijn, 2019, Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline, Eur Stroke J, 4, 198, 10.1177/2396987319841187

Gosselink, 1992, Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter, JAMA, 267, 3289, 10.1001/jama.1992.03480240051033

Scheuermeyer, 2013, Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness, Acad Emerg Med, 20, 222, 10.1111/acem.12091

Schreck, 1997, Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin, Ann Emerg Med, 29, 135, 10.1016/S0196-0644(97)70319-6

Segal, 2000, The evidence regarding the drugs used for ventricular rate control, J Fam Pract, 49, 47

Siu, 2009, Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation, Crit Care Med, 37, 2174, 10.1097/CCM.0b013e3181a02f56

Tisdale, 1998, A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery, Am Heart J, 135, 739, 10.1016/S0002-8703(98)70031-6

Darby, 2012, Management of atrial fibrillation in patients with structural heart disease, Circulation, 125, 945, 10.1161/CIRCULATIONAHA.111.019935

Kotecha, 2015, Atrial fibrillation in heart failure: what should we do?, Eur Heart J, 36, 3250

Delle Karth, 2001, Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias, Crit Care Med, 29, 1149, 10.1097/00003246-200106000-00011

Hou, 1995, Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study, Eur Heart J, 16, 521, 10.1093/oxfordjournals.eurheartj.a060945

Lim, 2007, Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial, Europace, 9, 498, 10.1093/europace/eum091

Queiroga, 2003, Ablate and pace revisited: long term survival and predictors of permanent atrial fibrillation, Heart, 89, 1035, 10.1136/heart.89.9.1035

Geelen, 1997, Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction, Pacing Clin Electrophysiol, 20, 343, 10.1111/j.1540-8159.1997.tb06179.x

Wang, 2013, Effect of pacing method on risk of sudden death after atrioventricular node ablation and pacemaker implantation in patients with atrial fibrillation, Heart Rhythm, 10, 696, 10.1016/j.hrthm.2013.01.021

Chatterjee, 2012, Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review, Circ Arrhythm Electrophysiol, 5, 68, 10.1161/CIRCEP.111.967810

Bradley, 2007, Overview of management of atrial fibrillation in symptomatic elderly patients: pharmacologic therapy versus AV node ablation, Clin Pharmacol Ther, 81, 284, 10.1038/sj.clpt.6100062

Ozcan, 2001, Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation, N Engl J Med, 344, 1043, 10.1056/NEJM200104053441403

Wood, 2000, Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis, Circulation, 101, 1138, 10.1161/01.CIR.101.10.1138

Brignole, 2013, 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA), Eur Heart J, 34, 2281, 10.1093/eurheartj/eht150

Chatterjee, 2012, Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode, Eur J Heart Fail, 14, 661, 10.1093/eurjhf/hfs036

Huang, 2018, Pacing treatment of atrial fibrillation patients with heart failure: His bundle pacing combined with atrioventricular node ablation, Card Electrophysiol Clin, 10, 519, 10.1016/j.ccep.2018.05.016

Brignole, 2018, A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS, Eur Heart J, 39, 3999, 10.1093/eurheartj/ehy555

Huang, 2017, Benefits of permanent His bundle pacing combined with atrioventricular node ablation in atrial fibrillation patients with heart failure with both preserved and reduced left ventricular ejection fraction, J Am Heart Assoc, 6, 10.1161/JAHA.116.005309

Farshi, 1999, Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens, J Am Coll Cardiol, 33, 304, 10.1016/S0735-1097(98)00561-0

Khand, 2003, Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?, J Am Coll Cardiol, 42, 1944, 10.1016/j.jacc.2003.07.020

Lewis, 1988, Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem, Eur Heart J, 9, 777, 10.1093/eurheartj/9.7.777

Mulder, 2014, Digoxin in patients with permanent atrial fibrillation: data from the RACE II study, Heart Rhythm, 11, 1543, 10.1016/j.hrthm.2014.06.007

Roth, 1986, Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation, Circulation, 73, 316, 10.1161/01.CIR.73.2.316

David, 1979, Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent, Am J Cardiol, 44, 1378, 10.1016/0002-9149(79)90456-9

Weerasooriya, 2003, The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT), J Am Coll Cardiol, 41, 1697, 10.1016/S0735-1097(03)00338-3

Vijayaraman, 2017, Atrioventricular node ablation and His bundle pacing, Europace, 19, iv10, 10.1093/europace/eux263

Shiga, 2017, Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: a crossover study of flecainide and pilsicainide, J Arrhythm, 33, 310, 10.1016/j.joa.2017.03.005

Capucci, 2016, Flecainide-metoprolol combination reduces atrial fibrillation clinical recurrences and improves tolerability at 1-year follow-up in persistent symptomatic atrial fibrillation, Europace, 18, 1698, 10.1093/europace/euv462

Shi, 2015, Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: a meta-analysis of randomized controlled trials, Exp Ther Med, 10, 816, 10.3892/etm.2015.2545

Siontis, 2016, Radiofrequency ablation versus antiarrhythmic drug therapy for atrial fibrillation: meta-analysis of quality of life, morbidity, and mortality, JACC Clin Electrophysiol, 2, 170, 10.1016/j.jacep.2015.10.003

Kim, 2016, Radiofrequency catheter ablation improves the quality of life measured with a short form-36 questionnaire in atrial fibrillation patients: a systematic review and meta-analysis, PLoS One, 11, e0163755, 10.1371/journal.pone.0163755

Bayes de Luna, 2012, Interatrial blocks. A separate entity from left atrial enlargement: a consensus report, J Electrocardiol, 45, 445, 10.1016/j.jelectrocard.2012.06.029

Jadidi, 2018, The duration of the amplified sinus-p-wave identifies presence of left atrial low voltage substrate and predicts outcome after pulmonary vein isolation in patients with persistent atrial fibrillation, JACC Clin Electrophysiol, 4, 531, 10.1016/j.jacep.2017.12.001

Dudink, 2018, The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey, Europace, 20, 929, 10.1093/europace/eux217

Zhang, 2013, Predictors of progression of recently diagnosed atrial fibrillation in REgistry on Cardiac Rhythm DisORDers Assessing the Control of Atrial Fibrillation (RecordAF) – United States cohort, Am J Cardiol, 112, 79, 10.1016/j.amjcard.2013.02.056

Bunch, 2013, Increasing time between first diagnosis of atrial fibrillation and catheter ablation adversely affects long-term outcomes, Heart Rhythm, 10, 1257, 10.1016/j.hrthm.2013.05.013

Andrade, 2018, A randomized clinical trial of early invasive intervention for atrial fibrillation (EARLY-AF) – methods and rationale, Am Heart J, 206, 94, 10.1016/j.ahj.2018.05.020

Teh, 2012, Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation, Heart Rhythm, 9, 473, 10.1016/j.hrthm.2011.11.013

Aliot, 2015, The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the Early treatment of Atrial fibrillation for Stroke prevention Trial, Eur Heart J, 36, 255

Michelena, 2010, Gender in atrial fibrillation: ten years later, Gend Med, 7, 206, 10.1016/j.genm.2010.06.001

Sethi, 2017, The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis, PLoS One, 12, e0186856, 10.1371/journal.pone.0186856

Ha, 2014, Health-related quality of life in patients with atrial fibrillation treated with rhythm control versus rate control: insights from a prospective international registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation: RECORD-AF), Circ Cardiovasc Qual Outcomes, 7, 896, 10.1161/HCQ.0000000000000011

Bulkova, 2014, Improvement in quality of life after catheter ablation for paroxysmal versus long-standing persistent atrial fibrillation: a prospective study with 3-year follow-up, J Am Heart Assoc, 3, 10.1161/JAHA.114.000881

Kirchhof, 2005, A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA), Eur Heart J, 26, 1292, 10.1093/eurheartj/ehi160

Kirchhof, 2002, Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial, Lancet, 360, 1275, 10.1016/S0140-6736(02)11315-8

Um, 2019, Pre- and post-treatment with amiodarone for elective electrical cardioversion of atrial fibrillation: a systematic review and meta-analysis, Europace, 21, 856, 10.1093/europace/euy310

Schmidt, 2020, Maximum-fixed energy shocks for cardioverting atrial fibrillation, Eur Heart J, 41, 626, 10.1093/eurheartj/ehz797

Pluymaekers, 2019, Early or delayed cardioversion in recent-onset atrial fibrillation, N Engl J Med, 380, 1499, 10.1056/NEJMoa1900353

Baranchuk, 2018, Advanced interatrial block predicts atrial fibrillation recurrence across different populations: learning Bayes syndrome, Int J Cardiol, 272, 221, 10.1016/j.ijcard.2018.08.025

Toufan, 2017, The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion, J Cardiovasc Thorac Res, 9, 54, 10.15171/jcvtr.2017.08

Voskoboinik, 2019, A comparison of early versus delayed elective electrical cardioversion for recurrent episodes of persistent atrial fibrillation: a multi-center study, Int J Cardiol, 284, 33, 10.1016/j.ijcard.2018.10.068

Furniss, 2015, Safe sedation in modern cardiological practice, Heart, 101, 1526, 10.1136/heartjnl-2015-307656

Mittal, 2000, Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks, Circulation, 101, 1282, 10.1161/01.CIR.101.11.1282

Inacio, 2016, Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: systematic review and network meta-analysis, Resuscitation, 100, 66, 10.1016/j.resuscitation.2015.12.009

Kirkland, 2014, The efficacy of pad placement for electrical cardioversion of atrial fibrillation/flutter: a systematic review, Acad Emerg Med, 21, 717, 10.1111/acem.12407

Boriani, 2004, Pharmacological cardioversion of atrial fibrillation: current management and treatment options, Drugs, 64, 2741, 10.2165/00003495-200464240-00003

Danias, 1998, Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm, J Am Coll Cardiol, 31, 588, 10.1016/S0735-1097(97)00534-2

Dan, 2018, Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP), Europace, 20, 731, 10.1093/europace/eux373

Markey, 2018, Intravenous flecainide for emergency department management of acute atrial fibrillation, J Emerg Med, 54, 320, 10.1016/j.jemermed.2017.11.016

Chevalier, 2003, Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis, J Am Coll Cardiol, 41, 255, 10.1016/S0735-1097(02)02705-5

Capucci, 1992, Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension, Am J Cardiol, 70, 69, 10.1016/0002-9149(92)91392-H

Donovan, 1992, Efficacy of flecainide for the reversion of acute onset atrial fibrillation, Am J Cardiol, 70, 10.1016/0002-9149(92)91078-I

Reisinger, 2004, Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset, Eur Heart J, 25, 1318, 10.1016/j.ehj.2004.04.030

Khan, 2003, Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation, Int J Cardiol, 87, 121, 10.1016/S0167-5273(02)00467-9

Galve, 1996, Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study, J Am Coll Cardiol, 27, 1079, 10.1016/0735-1097(95)00595-1

Vardas, 2000, Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study, Chest, 117, 1538, 10.1378/chest.117.6.1538

Letelier, 2003, Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis, Arch Intern Med, 163, 777, 10.1001/archinte.163.7.777

Bash, 2012, Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation, Cardiovasc Drugs Ther, 26, 167, 10.1007/s10557-012-6374-4

Camm, 2011, A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation, J Am Coll Cardiol, 57, 313, 10.1016/j.jacc.2010.07.046

Akel, 2018, Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: a meta-analysis, Ann Noninvasive Electrocardiol, 23, e12508, 10.1111/anec.12508

Beatch, 2016, Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial, BMC Cardiovasc Disord, 16, 113, 10.1186/s12872-016-0289-0

Roy, 2008, Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial, Circulation, 117, 1518, 10.1161/CIRCULATIONAHA.107.723866

Kowey, 2009, Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial, Circ Arrhythm Electrophysiol, 2, 652, 10.1161/CIRCEP.109.870204

Pohjantahti-Maaroos, 2019, Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation, Eur Heart J Acute Cardiovasc Care, 8, 114, 10.1177/2048872617728558

Vos, 1998, Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group, Heart, 79, 568, 10.1136/hrt.79.6.568

Alboni, 2004, Outpatient treatment of recent-onset atrial fibrillation with the ‘pill-in-the-pocket’ approach, N Engl J Med, 351, 2384, 10.1056/NEJMoa041233

Brembilla-Perrot, 2001, Predictors of atrial flutter with 1:1 conduction in patients treated with class I antiarrhythmic drugs for atrial tachyarrhythmias, Int J Cardiol, 80, 7, 10.1016/S0167-5273(01)00459-4

Zhang, 2005, Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation, Int J Clin Pract, 59, 1395, 10.1111/j.1368-5031.2005.00705.x

Conde, 2013, Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation, Int J Cardiol, 168, 2423, 10.1016/j.ijcard.2013.02.006

Martinez-Marcos, 2000, Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm, Am J Cardiol, 86, 950, 10.1016/S0002-9149(00)01128-0

Deedwania, 1998, Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators, Circulation, 98, 2574, 10.1161/01.CIR.98.23.2574

Hofmann, 2004, Intravenous amiodarone bolus for treatment of atrial fibrillation in patients with advanced congestive heart failure or cardiogenic shock, Wien Klin Wochenschr, 116, 744, 10.1007/s00508-004-0264-0

Crijns, 2014, Contemporary real life cardioversion of atrial fibrillation: results from the multinational RHYTHM-AF study, Int J Cardiol, 172, 588, 10.1016/j.ijcard.2014.01.099

Kirchhof, 2012, Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial, Lancet, 380, 238, 10.1016/S0140-6736(12)60570-4

Van Gelder, 1999, Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation, Am J Cardiol, 84, 147R, 10.1016/S0002-9149(99)00715-8

Climent, 2004, Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation, Pacing Clin Electrophysiol, 27, 368, 10.1111/j.1540-8159.2004.00444.x

Mussigbrodt, 2016, Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion, Europace, 18, 51, 10.1093/europace/euv194

Singh, 2009, Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial, Heart Rhythm, 6, 152, 10.1016/j.hrthm.2008.10.036

Oral, 1999, Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment, N Engl J Med, 340, 1849, 10.1056/NEJM199906173402401

Khan, 2001, Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation, J Am Coll Cardiol, 37, 542, 10.1016/S0735-1097(00)01116-5

Alboni, 2010, Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during ‘pill-in-the-pocket’ treatment, Heart, 96, 546, 10.1136/hrt.2009.187963

Arbelo, 2012, ESC-EURObservational Research Programme: the Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association, Europace, 14, 1094, 10.1093/europace/eus153

Arbelo, 2014, The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association, Eur Heart J, 35, 1466, 10.1093/eurheartj/ehu001

Arbelo, 2017, Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry, Eur Heart J, 38, 1303

Krittayaphong, 2003, A randomized clinical trial of the efficacy of radiofrequency catheter ablation and amiodarone in the treatment of symptomatic atrial fibrillation, J Med Assoc Thai, 86 Suppl 1, S8

Stabile, 2006, Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study), Eur Heart J, 27, 216, 10.1093/eurheartj/ehi583

Pappone, 2006, A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study, J Am Coll Cardiol, 48, 2340, 10.1016/j.jacc.2006.08.037

Calkins, 2009, Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses, Circ Arrhythm Electrophysiol, 2, 349, 10.1161/CIRCEP.108.824789

Packer, 2013, Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial, J Am Coll Cardiol, 61, 1713, 10.1016/j.jacc.2012.11.064

Ganesan, 2013, Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis, J Am Heart Assoc, 2, e004549, 10.1161/JAHA.112.004549

Di Biase, 2016, Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial, Circulation, 133, 1637, 10.1161/CIRCULATIONAHA.115.019406

Kuck, 2016, Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation, N Engl J Med, 374, 2235, 10.1056/NEJMoa1602014

Sohara, 2016, HotBalloon ablation of the pulmonary veins for paroxysmal AF: a multicenter randomized trial in Japan, J Am Coll Cardiol, 68, 2747, 10.1016/j.jacc.2016.10.037

Hakalahti, 2015, Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis, Europace, 17, 370, 10.1093/europace/euu376

Nielsen, 2017, Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trial, Heart, 103, 368, 10.1136/heartjnl-2016-309781

Chen, 2018, Catheter ablation versus medical therapy for patients with persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized controlled trials, J Interv Card Electrophysiol, 52, 9, 10.1007/s10840-018-0349-8

Packer, 2019, Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1261, 10.1001/jama.2019.0693

Noseworthy, 2019, Atrial fibrillation ablation in practice: assessing CABANA generalizability, Eur Heart J, 40, 1257, 10.1093/eurheartj/ehz085

Teh, 2012, Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease, J Cardiovasc Electrophysiol, 23, 232, 10.1111/j.1540-8167.2011.02178.x

D'Ascenzo, 2013, Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis, Int J Cardiol, 167, 1984, 10.1016/j.ijcard.2012.05.008

Berruezo, 2007, Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation, Eur Heart J, 28, 836, 10.1093/eurheartj/ehm027

Nedios, 2015, Comparison of left atrial dimensions in CT and echocardiography as predictors of long-term success after catheter ablation of atrial fibrillation, J Interv Card Electrophysiol, 43, 237, 10.1007/s10840-015-0010-8

Njoku, 2018, Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a meta-analysis, Europace, 20, 33, 10.1093/europace/eux013

Costa, 2015, Left atrial volume is more important than the type of atrial fibrillation in predicting the long-term success of catheter ablation, Int J Cardiol, 184, 56, 10.1016/j.ijcard.2015.01.060

Marrouche, 2014, Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study, JAMA, 311, 498, 10.1001/jama.2014.3

Kosich, 2019, Clinical scores used for the prediction of negative events in patients undergoing catheter ablation for atrial fibrillation, Clin Cardiol, 42, 320, 10.1002/clc.23139

Kornej, 2015, The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation, Clin Res Cardiol, 104, 871, 10.1007/s00392-015-0856-x

Kornej, 2017, The APPLE score – a novel score for the prediction of rhythm outcomes after repeat catheter ablation of atrial fibrillation, PLoS One, 12, e0169933, 10.1371/journal.pone.0169933

Kornej, 2018, Prediction of electro-anatomical substrate and arrhythmia recurrences using APPLE, DR-FLASH and MB-LATER scores in patients with atrial fibrillation undergoing catheter ablation, Sci Rep, 8, 12686, 10.1038/s41598-018-31133-x

Kosiuk, 2015, Prospective, multicenter validation of a clinical risk score for left atrial arrhythmogenic substrate based on voltage analysis: DR-FLASH score, Heart Rhythm, 12, 2207, 10.1016/j.hrthm.2015.07.003

Mujovic, 2017, Prediction of very late arrhythmia recurrence after radiofrequency catheter ablation of atrial fibrillation: the MB-LATER clinical score, Sci Rep, 7, 40828, 10.1038/srep40828

Mesquita, 2018, Development and validation of a risk score for predicting atrial fibrillation recurrence after a first catheter ablation procedure – ATLAS score, Europace, 20, f428, 10.1093/europace/eux265

Winkle, 2016, Predicting atrial fibrillation ablation outcome: the CAAP-AF score, Heart Rhythm, 13, 2119, 10.1016/j.hrthm.2016.07.018

Canpolat, 2013, A proposal for a new scoring system in the prediction of catheter ablation outcomes: promising results from the Turkish Cryoablation Registry, Int J Cardiol, 169, 201, 10.1016/j.ijcard.2013.08.097

Wojcik, 2013, Repeated catheter ablation of atrial fibrillation: how to predict outcome?, Circ J, 77, 2271, 10.1253/circj.CJ-13-0308

Pathak, 2014, Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study, J Am Coll Cardiol, 64, 2222, 10.1016/j.jacc.2014.09.028

Trines, 2019, Influence of risk factors in the ESC-EHRA EORP atrial fibrillation ablation long-term registry, Pacing Clin Electrophysiol, 42, 1365, 10.1111/pace.13763

Wong, 2015, Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: a meta-analysis of 626,603 individuals in 51 studies, JACC Clin Electrophysiol, 1, 139, 10.1016/j.jacep.2015.04.004

Wokhlu, 2010, Long-term outcome of atrial fibrillation ablation: impact and predictors of very late recurrence, J Cardiovasc Electrophysiol, 21, 1071, 10.1111/j.1540-8167.2010.01786.x

Arya, 2010, Long-term results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients, Europace, 12, 173, 10.1093/europace/eup331

Santoro, 2015, Impact of uncontrolled hypertension on atrial fibrillation ablation outcome, JACC Clin Electrophysiol, 1, 164, 10.1016/j.jacep.2015.04.002

Letsas, 2009, Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation, Europace, 11, 158, 10.1093/europace/eun309

Jongnarangsin, 2008, Body mass index, obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation, J Cardiovasc Electrophysiol, 19, 668, 10.1111/j.1540-8167.2008.01118.x

Patel, 2010, Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure, Circ Arrhythm Electrophysiol, 3, 445, 10.1161/CIRCEP.109.858381

Matiello, 2010, Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients, Europace, 12, 1084, 10.1093/europace/euq128

Chilukuri, 2010, A prospective study evaluating the role of obesity and obstructive sleep apnea for outcomes after catheter ablation of atrial fibrillation, J Cardiovasc Electrophysiol, 21, 521, 10.1111/j.1540-8167.2009.01653.x

Ng, 2011, Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation, Am J Cardiol, 108, 47, 10.1016/j.amjcard.2011.02.343

Naruse, 2013, Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy, Heart Rhythm, 10, 331, 10.1016/j.hrthm.2012.11.015

Li, 2014, Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies, Europace, 16, 1309, 10.1093/europace/euu066

Kawakami, 2016, Apnea-hypopnea index as a predictor of atrial fibrillation recurrence following initial pulmonary vein isolation: usefulness of type-3 portable monitor for sleep-disordered breathing, J Interv Card Electrophysiol, 47, 237, 10.1007/s10840-016-0148-z

Congrete, 2018, Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: a meta-analysis, J Evid Based Med, 11, 145, 10.1111/jebm.12313

Deng, 2018, Treating obstructive sleep apnea with continuous positive airway pressure reduces risk of recurrent atrial fibrillation after catheter ablation: a meta-analysis, Sleep Med, 46, 5, 10.1016/j.sleep.2018.02.013

Wokhlu, 2010, Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect, J Am Coll Cardiol, 55, 2308, 10.1016/j.jacc.2010.01.040

Reddy, 2015, Randomized, controlled trial of the safety and effectiveness of a contact force-sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) Study, Circulation, 132, 907, 10.1161/CIRCULATIONAHA.114.014092

Mark, 2019, Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial, JAMA, 321, 1275, 10.1001/jama.2019.0692

Kirchhof, 2013, Improving outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial fibrillation for Stroke prevention Trial, Am Heart J, 166, 442, 10.1016/j.ahj.2013.05.015

Marrouche, 2018, Catheter ablation for atrial fibrillation with heart failure, N Engl J Med, 378, 417, 10.1056/NEJMoa1707855

Noseworthy, 2020, Generalizability of the CASTLE-AF trial: catheter ablation for patients with atrial fibrillation and heart failure in routine practice, Heart Rhythm, 10.1016/j.hrthm.2020.02.030

Kuck, 2019, Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial, Circ Arrhythm Electrophysiol, 12, e007731, 10.1161/CIRCEP.119.007731

Khan, 2008, Pulmonary-vein isolation for atrial fibrillation in patients with heart failure, N Engl J Med, 359, 1778, 10.1056/NEJMoa0708234

MacDonald, 2011, Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial, Heart, 97, 740, 10.1136/hrt.2010.207340

Jones, 2013, randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure, J Am Coll Cardiol, 61, 1894, 10.1016/j.jacc.2013.01.069

Hunter, 2014, A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial), Circ Arrhythm Electrophysiol, 7, 31, 10.1161/CIRCEP.113.000806

Al Halabi, 2015, Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials, JACC Clin Electrophysiol, 1, 200, 10.1016/j.jacep.2015.02.018

Prabhu, 2017, Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study, J Am Coll Cardiol, 70, 1949, 10.1016/j.jacc.2017.08.041

Elgendy, 2018, Meta-analysis comparing catheter-guided ablation versus conventional medical therapy for patients with atrial fibrillation and heart failure with reduced ejection fraction, Am J Cardiol, 122, 806, 10.1016/j.amjcard.2018.05.009

Briceno, 2018, Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials, J Interv Card Electrophysiol, 53, 19, 10.1007/s10840-018-0425-0

Ma, 2018, Catheter ablation for treatment of patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials, BMC Cardiovasc Disord, 18, 165, 10.1186/s12872-018-0904-3

Kheiri, 2018, Catheter ablation of atrial fibrillation with heart failure: an updated meta-analysis of randomized trials, Int J Cardiol, 269, 170, 10.1016/j.ijcard.2018.07.024

Khan, 2018, The clinical benefits and mortality reduction associated with catheter ablation in subjects with atrial fibrillation: a systematic review and meta-analysis, JACC Clin Electrophysiol, 4, 626, 10.1016/j.jacep.2018.03.003

Martin, 2017, Pathophysiology, diagnosis and treatment of tachycardiomyopathy, Heart, 103, 1543, 10.1136/heartjnl-2016-310391

Raymond-Paquin, 2018, Mechanisms and clinical significance of arrhythmia-induced cardiomyopathy, Can J Cardiol, 34, 1449, 10.1016/j.cjca.2018.07.475

Brembilla-Perrot, 2016, Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation, Eur J Heart Fail, 18, 394, 10.1002/ejhf.482

Dagres, 2011, Catheter ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review and meta-analysis, J Card Fail, 17, 964, 10.1016/j.cardfail.2011.07.009

Prabhu, 2018, Regression of diffuse ventricular fibrosis following restoration of sinus rhythm with catheter ablation in patients with atrial fibrillation and systolic dysfunction: a substudy of the CAMERA MRI trial, JACC Clin Electrophysiol, 4, 999, 10.1016/j.jacep.2018.04.013

Tamborero, 2009, Left atrial posterior wall isolation does not improve the outcome of circumferential pulmonary vein ablation for atrial fibrillation: a prospective randomized study, Circ Arrhythm Electrophysiol, 2, 35, 10.1161/CIRCEP.108.797944

Natale, 2014, Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial, J Am Coll Cardiol, 64, 647, 10.1016/j.jacc.2014.04.072

McLellan, 2015, A minimal or maximal ablation strategy to achieve pulmonary vein isolation for paroxysmal atrial fibrillation: a prospective multi-centre randomized controlled trial (the Minimax study), Eur Heart J, 36, 1812, 10.1093/eurheartj/ehv139

Verma, 2015, Approaches to catheter ablation for persistent atrial fibrillation, N Engl J Med, 372, 1812, 10.1056/NEJMoa1408288

Luik, 2015, Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: the prospective, randomized, controlled, noninferiority FreezeAF study, Circulation, 132, 1311, 10.1161/CIRCULATIONAHA.115.016871

Dukkipati, 2015, Pulmonary vein isolation using the visually guided laser balloon: a prospective, multicenter, and randomized comparison to standard radiofrequency ablation, J Am Coll Cardiol, 66, 1350, 10.1016/j.jacc.2015.07.036

Kuck, 2016, Impact of complete versus incomplete circumferential lines around the pulmonary veins during catheter ablation of paroxysmal atrial fibrillation: results from the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 trial, Circ Arrhythm Electrophysiol, 9, e003337, 10.1161/CIRCEP.115.003337

Nery, 2016, Relationship between pulmonary vein reconnection and atrial fibrillation recurrence: a systematic review and meta-analysis, JACC Clin Electrophysiol, 2, 474, 10.1016/j.jacep.2016.02.003

Bassiouny, 2016, Randomized study of persistent atrial fibrillation ablation: ablate in sinus rhythm versus ablate complex-fractionated atrial electrograms in atrial fibrillation, Circ Arrhythm Electrophysiol, 9, e003596, 10.1161/CIRCEP.115.003596

Hindricks, 2018, Catheter ablation of atrial fibrillation: current status, techniques, outcomes and challenges, Kardiol Pol, 76, 1680, 10.5603/KP.a2018.0216

Nanthakumar, 2004, Resumption of electrical conduction in previously isolated pulmonary veins: rationale for a different strategy?, Circulation, 109, 1226, 10.1161/01.CIR.0000121423.78120.49

Verma, 2005, Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction, Circulation, 112, 627, 10.1161/CIRCULATIONAHA.104.533190

Ouyang, 2005, Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique, Circulation, 111, 127, 10.1161/01.CIR.0000151289.73085.36

Cheema, 2007, Incidence and time course of early recovery of pulmonary vein conduction after catheter ablation of atrial fibrillation, J Cardiovasc Electrophysiol, 18, 387, 10.1111/j.1540-8167.2007.00760.x

Pratola, 2008, Radiofrequency ablation of atrial fibrillation: is the persistence of all intraprocedural targets necessary for long-term maintenance of sinus rhythm?, Circulation, 117, 136, 10.1161/CIRCULATIONAHA.106.678789

Rajappan, 2008, Acute and chronic pulmonary vein reconnection after atrial fibrillation ablation: a prospective characterization of anatomical sites, Pacing Clin Electrophysiol, 31, 1598, 10.1111/j.1540-8159.2008.01232.x

Bansch, 2013, Circumferential pulmonary vein isolation: wait or stop early after initial successful pulmonary vein isolation?, Europace, 15, 183, 10.1093/europace/eus205

Nakamura, 2013, Optimal observation time after completion of circumferential pulmonary vein isolation for atrial fibrillation to prevent chronic pulmonary vein reconnections, Int J Cardiol, 168, 5300, 10.1016/j.ijcard.2013.08.011

Neuzil, 2013, Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: results from the EFFICAS I study, Circ Arrhythm Electrophysiol, 6, 327, 10.1161/CIRCEP.113.000374

Jiang, 2014, Incidence of pulmonary vein conduction recovery in patients without clinical recurrence after ablation of paroxysmal atrial fibrillation: mechanistic implications, Heart Rhythm, 11, 969, 10.1016/j.hrthm.2014.03.015

Kim, 2017, Pulmonary vein reconnection predicts good clinical outcome after second catheter ablation for atrial fibrillation, Europace, 19, 961

Bordignon, 2015, High rate of durable pulmonary vein isolation after second-generation cryoballoon ablation: analysis of repeat procedures, Europace, 17, 725, 10.1093/europace/euu331

Ullah, 2016, Randomized trial comparing pulmonary vein isolation using the SmartTouch catheter with or without real-time contact force data, Heart Rhythm, 13, 1761, 10.1016/j.hrthm.2016.05.011

Phlips, 2018, Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the ‘CLOSE’-protocol, Europace, 20, f419, 10.1093/europace/eux376

Shah, 2003, Nonpulmonary vein foci: do they exist?, Pacing Clin Electrophysiol, 26, 1631, 10.1046/j.1460-9592.2003.t01-1-00243.x

Nademanee, 2004, A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate, J Am Coll Cardiol, 43, 2044, 10.1016/j.jacc.2003.12.054

Haissaguerre, 2005, Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination, J Cardiovasc Electrophysiol, 16, 1125, 10.1111/j.1540-8167.2005.00307.x

Haissaguerre, 2005, Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias, J Cardiovasc Electrophysiol, 16, 1138, 10.1111/j.1540-8167.2005.00308.x

Jaïs, 2006, Stepwise catheter ablation of chronic atrial fibrillation:importance of discrete anatomic sites for termination, J Cardiovasc Electrophysiol, 17, S28, 10.1111/j.1540-8167.2006.00652.x

Atienza, 2009, Real-time dominant frequency mapping and ablation of dominant frequency sites in atrial fibrillation with left-to-right frequency gradients predicts long-term maintenance of sinus rhythm, Heart Rhythm, 6, 33, 10.1016/j.hrthm.2008.10.024

Stavrakis, 2015, The role of the autonomic ganglia in atrial fibrillation, JACC Clin Electrophysiol, 1, 1, 10.1016/j.jacep.2015.01.005

Di Biase, 2016, Left atrial appendage isolation in patients with longstanding persistent af undergoing catheter ablation: BELIEF trial, J Am Coll Cardiol, 68, 1929, 10.1016/j.jacc.2016.07.770

Gianni, 2016, Acute and early outcomes of focal impulse and rotor modulation (FIRM)-guided rotors-only ablation in patients with nonparoxysmal atrial fibrillation, Heart Rhythm, 13, 830, 10.1016/j.hrthm.2015.12.028

Santangeli, 2016, Prevalence and distribution of focal triggers in persistent and long-standing persistent atrial fibrillation, Heart Rhythm, 13, 374, 10.1016/j.hrthm.2015.10.023

Katritsis, 2013, Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial, J Am Coll Cardiol, 62, 2318, 10.1016/j.jacc.2013.06.053

Arbelo, 2014, Benefit of left atrial roof linear ablation in paroxysmal atrial fibrillation: a prospective, randomized study, J Am Heart Assoc, 3, e000877, 10.1161/JAHA.114.000877

Da Costa, 2015, Remote-controlled magnetic pulmonary vein isolation combined with superior vena cava isolation for paroxysmal atrial fibrillation: a prospective randomized study, Arch Cardiovasc Dis, 108, 163, 10.1016/j.acvd.2014.10.005

Wong, 2015, No benefit of complex fractionated atrial electrogram ablation in addition to circumferential pulmonary vein ablation and linear ablation: Benefit of Complex Ablation Study, Circ Arrhythm Electrophysiol, 8, 1316, 10.1161/CIRCEP.114.002504

Vogler, 2015, Pulmonary vein isolation versus defragmentation: the CHASE-AF clinical trial, J Am Coll Cardiol, 66, 2743, 10.1016/j.jacc.2015.09.088

Faustino, 2015, Stepwise ablation approach versus pulmonary vein isolation in patients with paroxysmal atrial fibrillation: randomized controlled trial, Heart Rhythm, 12, 1907, 10.1016/j.hrthm.2015.06.009

Scott, 2016, The impact of adjunctive complex fractionated atrial electrogram ablation and linear lesions on outcomes in persistent atrial fibrillation: a meta-analysis, Europace, 18, 359, 10.1093/europace/euv351

Driessen, 2016, Ganglion plexus ablation in advanced atrial fibrillation: the AFACT study, J Am Coll Cardiol, 68, 1155, 10.1016/j.jacc.2016.06.036

Qin, 2016, Atrial substrate modification in atrial fibrillation: targeting GP or CFAE? Evidence from meta-analysis of clinical trials, PLoS One, 11, e0164989, 10.1371/journal.pone.0164989

Hu, 2016, Is there still a role for additional linear ablation in addition to pulmonary vein isolation in patients with paroxysmal atrial fibrillation? An updated meta-analysis of randomized controlled trials, Int J Cardiol, 209, 266, 10.1016/j.ijcard.2016.02.076

Wynn, 2016, Biatrial linear ablation in sustained nonpermanent AF: results of the substrate modification with ablation and antiarrhythmic drugs in nonpermanent atrial fibrillation (SMAN-PAF) trial, Heart Rhythm, 13, 399, 10.1016/j.hrthm.2015.10.006

Zhang, 2016, Linear ablation following pulmonary vein isolation in patients with atrial fibrillation: a meta-analysis, Pacing Clin Electrophysiol, 39, 623, 10.1111/pace.12841

Fink, 2017, Stand-alone pulmonary vein isolation versus pulmonary vein isolation with additional substrate modification as index ablation procedures in patients with persistent and long-standing persistent atrial fibrillation: the randomized Alster-Lost-AF trial (Ablation at St. Georg Hospital for long-standing persistent atrial fibrillation, Circ Arrhythm Electrophysiol, 10, 10.1161/CIRCEP.117.005114

Kim, 2017, Does additional electrogram-guided ablation after linear ablation reduce recurrence after catheter ablation for longstanding persistent atrial fibrillation? A prospective randomized study, J Am Heart Assoc, 6, e004811, 10.1161/JAHA.116.004811

Kircher, 2018, Individually tailored vs. standardized substrate modification during radiofrequency catheter ablation for atrial fibrillation: a randomized study, Europace, 20, 1766, 10.1093/europace/eux310

Ammar-Busch, 2017, Ablation of complex fractionated electrograms with or without ADditional LINEar Lesions for Persistent Atrial Fibrillation (the ADLINE trial), J Cardiovasc Electrophysiol, 28, 636, 10.1111/jce.13206

Blandino, 2017, Left atrial substrate modification targeting low-voltage areas for catheter ablation of atrial fibrillation: a systematic review and meta-analysis, Pacing Clin Electrophysiol, 40, 199, 10.1111/pace.13015

Yang, 2017, STABLE-SR (Electrophysiological Substrate Ablation in the Left Atrium During Sinus Rhythm) for the treatment of nonparoxysmal atrial fibrillation: a prospective, multicenter randomized clinical trial, Circ Arrhythm Electrophysiol, 10, 10.1161/CIRCEP.117.005405

Yu, 2017, Pulmonary vein isolation alone versus additional linear ablation in patients with persistent atrial fibrillation converted to paroxysmal type with antiarrhythmic drug therapy: a multicenter, prospective, randomized study, Circ Arrhythm Electrophysiol, 10, 10.1161/CIRCEP.116.004915

Wang, 2018, Optimal endpoint for catheter ablation of longstanding persistent atrial fibrillation: a randomized clinical trial, Pacing Clin Electrophysiol, 41, 172, 10.1111/pace.13221

Perez, 2009, Long-term outcomes after catheter ablation of cavo-tricuspid isthmus dependent atrial flutter: a meta-analysis, Circ Arrhythm Electrophysiol, 2, 393, 10.1161/CIRCEP.109.871665

Natale, 2000, Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter, J Am Coll Cardiol, 35, 1898, 10.1016/S0735-1097(00)00635-5

Wazni, 2003, Randomized study comparing combined pulmonary vein-left atrial junction disconnection and cavotricuspid isthmus ablation versus pulmonary vein-left atrial junction disconnection alone in patients presenting with typical atrial flutter and atrial fibrillation, Circulation, 108, 2479, 10.1161/01.CIR.0000101684.88679.AB

Shah, 2007, Evaluation of an individualized strategy of cavotricuspid isthmus ablation as an adjunct to atrial fibrillation ablation, J Cardiovasc Electrophysiol, 18, 926, 10.1111/j.1540-8167.2007.00896.x

Neumann, 2011, MEDAFI-Trial (Micro-embolization during ablation of atrial fibrillation): comparison of pulmonary vein isolation using cryoballoon technique vs. radiofrequency energy, Europace, 13, 37, 10.1093/europace/euq303

Herrera Siklody, 2011, Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study, J Am Coll Cardiol, 58, 681, 10.1016/j.jacc.2011.04.010

Herrera Siklody, 2012, Cellular damage, platelet activation, and inflammatory response after pulmonary vein isolation: a randomized study comparing radiofrequency ablation with cryoablation, Heart Rhythm, 9, 189, 10.1016/j.hrthm.2011.09.017

Pokushalov, 2013, Cryoballoon versus radiofrequency for pulmonary vein re-isolation after a failed initial ablation procedure in patients with paroxysmal atrial fibrillation, J Cardiovasc Electrophysiol, 24, 274, 10.1111/jce.12038

Schmidt, 2014, Cryoballoon versus RF ablation in paroxysmal atrial fibrillation: results from the German Ablation Registry, J Cardiovasc Electrophysiol, 25, 1, 10.1111/jce.12267

Perez-Castellano, 2014, The COR trial: a randomized study with continuous rhythm monitoring to compare the efficacy of cryoenergy and radiofrequency for pulmonary vein isolation, Heart Rhythm, 11, 8, 10.1016/j.hrthm.2013.10.014

Hunter, 2015, Point-by-point radiofrequency ablation versus the cryoballoon or a novel combined approach: a randomized trial comparing 3 methods of pulmonary vein isolation for paroxysmal atrial fibrillation (the Cryo Versus RF trial), J Cardiovasc Electrophysiol, 26, 1307, 10.1111/jce.12846

Squara, 2015, Comparison between radiofrequency with contact force-sensing and second-generation cryoballoon for paroxysmal atrial fibrillation catheter ablation: a multicentre European evaluation, Europace, 17, 718, 10.1093/europace/euv060

Straube, 2016, First-line catheter ablation of paroxysmal atrial fibrillation: outcome of radiofrequency vs. cryoballoon pulmonary vein isolation, Europace, 18, 368, 10.1093/europace/euv271

Schmidt, 2016, German ablation registry: cryoballoon vs. radiofrequency ablation in paroxysmal atrial fibrillation – one-year outcome data, Heart Rhythm, 13, 836, 10.1016/j.hrthm.2015.12.007

Boveda, 2016, Outcomes after cryoballoon or radiofrequency ablation for persistent atrial fibrillation: a multicentric propensity-score matched study, J Interv Card Electrophysiol, 47, 133, 10.1007/s10840-016-0138-1

Kuck, 2016, Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial, Eur Heart J, 37, 2858, 10.1093/eurheartj/ehw285

Buist, 2018, Arrhythmia-free survival and pulmonary vein reconnection patterns after second-generation cryoballoon and contact-force radiofrequency pulmonary vein isolation, Clin Res Cardiol, 107, 498, 10.1007/s00392-018-1211-9

Gunawardene, 2018, Influence of energy source on early atrial fibrillation recurrences: a comparison of cryoballoon vs. radiofrequency current energy ablation with the endpoint of unexcitability in pulmonary vein isolation, Europace, 20, 43

Mortsell, 2019, Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry, Europace, 21, 581, 10.1093/europace/euy239

Akkaya, 2018, Ice or fire? Comparison of second-generation cryoballoon ablation and radiofrequency ablation in patients with symptomatic persistent atrial fibrillation and an enlarged left atrium, J Cardiovasc Electrophysiol, 29, 375, 10.1111/jce.13402

Murray, 2018, Cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation: a meta-analysis of randomized controlled trials, Clin Res Cardiol, 107, 658, 10.1007/s00392-018-1232-4

Chen, 2017, Comparison of catheter ablation for paroxysmal atrial fibrillation between cryoballoon and radiofrequency: a meta-analysis, J Interv Card Electrophysiol, 48, 351, 10.1007/s10840-016-0220-8

Buiatti, 2017, Cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: an updated meta-analysis of randomized and observational studies, Europace, 19, 378, 10.1093/europace/euw262

Cardoso, 2016, Cryoballoon versus radiofrequency catheter ablation in atrial fibrillation: a meta-analysis, J Cardiovasc Electrophysiol, 27, 1151, 10.1111/jce.13047

Kabunga, 2016, Meta-analysis of contemporary atrial fibrillation ablation strategies: irrigated radiofrequency versus duty-cycled phased radiofrequency versus cryoballoon ablation, JACC Clin Electrophysiol, 2, 377, 10.1016/j.jacep.2015.12.013

Bollmann, 2018, Cardiac tamponade in catheter ablation of atrial fibrillation: German-wide analysis of 21 141 procedures in the Helios atrial fibrillation ablation registry (SAFER), Europace, 20, 1944, 10.1093/europace/euy131

Ueberham, 2018, SAFER, Eur Heart J, 39, 2023, 10.1093/eurheartj/ehy255

Hummel, 2014, Phased RF ablation in persistent atrial fibrillation, Heart Rhythm, 11, 202, 10.1016/j.hrthm.2013.11.009

Boersma, 2016, Multielectrode pulmonary vein isolation versus single tip wide area catheter ablation for paroxysmal atrial fibrillation: a multinational multicenter randomized clinical trial, Circ Arrhythm Electrophysiol, 9, e003151, 10.1161/CIRCEP.115.003151

Nagashima, 2018, Hot balloon versus cryoballoon ablation for atrial fibrillation: lesion characteristics and middle-term outcomes, Circ Arrhythm Electrophysiol, 11, e005861, 10.1161/CIRCEP.117.005861

Ucer, 2018, A RAndomized Trial to compare the acute reconnection after pulmonary vein ISolation with Laser-BalloON versus radiofrequency Ablation: RATISBONA trial, J Cardiovasc Electrophysiol, 29, 733, 10.1111/jce.13465

De Greef, 2018, Complications of pulmonary vein isolation in atrial fibrillation: predictors and comparison between four different ablation techniques: results from the Middelheim PVI-registry, Europace, 20, 1279, 10.1093/europace/eux233

Steinbeck, 2018, Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014, Eur Heart J, 39, 4020, 10.1093/eurheartj/ehy452

Fink, 2019, Procedural success, safety and patients satisfaction after second ablation of atrial fibrillation in the elderly: results from the German ablation registry, Clin Res Cardiol, 10.1007/s00392-019-01471-5

Szegedi, 2019, Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation, Europace, 21, 732, 10.1093/europace/euy326

Cappato, 2010, Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation, Circ Arrhythm Electrophysiol, 3, 32, 10.1161/CIRCEP.109.859116

Lee, 2011, Low risk of major complications associated with pulmonary vein antral isolation for atrial fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural heart disease from a single center, J Cardiovasc Electrophysiol, 22, 163

Deshmukh, 2013, In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures, Circulation, 128, 2104, 10.1161/CIRCULATIONAHA.113.003862

Tripathi, 2018, Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States: an update from Nationwide Inpatient Sample database (2011–2014, J Cardiovasc Electrophysiol, 29, 715, 10.1111/jce.13471

Voskoboinik, 2018, Low rates of major complications for radiofrequency ablation of atrial fibrillation maintained over 14 years: a single centre experience of 2750 consecutive cases, Heart Lung Circ, 27, 976, 10.1016/j.hlc.2018.01.002

Berger, 2019, Persistent atrial fibrillation: a systematic review and meta-analysis of invasive strategies, Int J Cardiol, 278, 137, 10.1016/j.ijcard.2018.11.127

Shah, 2008, Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence, J Cardiovasc Electrophysiol, 19, 661, 10.1111/j.1540-8167.2008.01101.x

Sawhney, 2009, Five-year outcomes after segmental pulmonary vein isolation for paroxysmal atrial fibrillation, Am J Cardiol, 104, 366, 10.1016/j.amjcard.2009.03.044

Ouyang, 2010, Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up, Circulation, 122, 2368, 10.1161/CIRCULATIONAHA.110.946806

Bertaglia, 2010, Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation ablation: a 6-year multicentre experience, Europace, 12, 181, 10.1093/europace/eup349

Weerasooriya, 2011, Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?, J Am Coll Cardiol, 57, 160, 10.1016/j.jacc.2010.05.061

Medi, 2011, Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up, J Cardiovasc Electrophysiol, 22, 137

Schreiber, 2015, Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success, Circ Arrhythm Electrophysiol, 8, 308, 10.1161/CIRCEP.114.001672

Scherr, 2015, Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint, Circ Arrhythm Electrophysiol, 8, 18, 10.1161/CIRCEP.114.001943

Bertaglia, 2017, Twelve-year follow-up of catheter ablation for atrial fibrillation: a prospective, multicenter, randomized study, Heart Rhythm, 14, 486, 10.1016/j.hrthm.2016.12.023

Skelly, 2015

Zheng, 2015, Long-term stroke rates after catheter ablation or antiarrhythmic drug therapy for atrial fibrillation: a meta-analysis of randomized trials, J Geriatr Cardiol, 12, 507

Reynolds, 2010, Improvements in symptoms and quality of life in patients with paroxysmal atrial fibrillation treated with radiofrequency catheter ablation versus antiarrhythmic drugs, Circ Cardiovasc Qual Outcomes, 3, 615, 10.1161/CIRCOUTCOMES.110.957563

Walfridsson, 2015, Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial, Europace, 17, 215, 10.1093/europace/euu342

De Greef, 2018, Diagnosis-to-ablation time as a predictor of success: early choice for pulmonary vein isolation and long-term outcome in atrial fibrillation: results from the Middelheim-PVI registry, Europace, 20, 589, 10.1093/europace/euw426

Wong, 2011, Pericardial fat is associated with atrial fibrillation severity and ablation outcome, J Am Coll Cardiol, 57, 1745, 10.1016/j.jacc.2010.11.045

Kang, 2012, Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion, J Cardiovasc Electrophysiol, 23, 1165, 10.1111/j.1540-8167.2012.02339.x

Mahajan, 2015, Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity, J Am Coll Cardiol, 66, 1, 10.1016/j.jacc.2015.04.058

Winkle, 2017, Impact of obesity on atrial fibrillation ablation: patient characteristics, long-term outcomes, and complications, Heart Rhythm, 14, 819, 10.1016/j.hrthm.2017.02.023

De Maat, 2018, Obesity is associated with impaired long-term success of pulmonary vein isolation: a plea for risk factor management before ablation, Open Heart, 5, e000771, 10.1136/openhrt-2017-000771

Glover, 2019, Impact of body mass index on the outcome of catheter ablation of atrial fibrillation, Heart, 105, 244, 10.1136/heartjnl-2018-313490

Chang, 2009, Comparison of outcome in catheter ablation of atrial fibrillation in patients with versus without the metabolic syndrome, Am J Cardiol, 103, 67, 10.1016/j.amjcard.2008.08.042

Tang, 2009, Metabolic syndrome and risk of recurrence of atrial fibrillation after catheter ablation, Circ J, 73, 438, 10.1253/circj.CJ-08-0832

Mohanty, 2012, Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation, J Am Coll Cardiol, 59, 1295, 10.1016/j.jacc.2011.11.051

Mulder, 2012, Arrhythmia detection after atrial fibrillation ablation: value of incremental monitoring time, Pacing Clin Electrophysiol, 35, 164, 10.1111/j.1540-8159.2011.03202.x

Steven, 2008, What is the real atrial fibrillation burden after catheter ablation of atrial fibrillation? A prospective rhythm analysis in pacemaker patients with continuous atrial monitoring, Eur Heart J, 29, 1037, 10.1093/eurheartj/ehn024

Kaitani, 2016, Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial, Eur Heart J, 37, 610, 10.1093/eurheartj/ehv501

Willems, 2016, Redefining the blanking period after catheter ablation for paroxysmal atrial fibrillation: insights from the ADVICE (Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination) trial, Circ Arrhythm Electrophysiol, 9, e003909, 10.1161/CIRCEP.115.003909

Klemm, 2006, Correlation of symptoms to ECG diagnosis following atrial fibrillation ablation, J Cardiovasc Electrophysiol, 17, 146, 10.1111/j.1540-8167.2005.00288.x

Vasamreddy, 2006, Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation, J Cardiovasc Electrophysiol, 17, 134, 10.1111/j.1540-8167.2006.00359.x

Oral, 2004, Prevalence of asymptomatic recurrences of atrial fibrillation after successful radiofrequency catheter ablation, J Cardiovasc Electrophysiol, 15, 920, 10.1046/j.1540-8167.2004.04055.x

Hindricks, 2005, Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence, Circulation, 112, 307, 10.1161/CIRCULATIONAHA.104.518837

Senatore, 2005, Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation, J Am Coll Cardiol, 45, 873, 10.1016/j.jacc.2004.11.050

Roux, 2009, Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study), Circulation, 120, 1036, 10.1161/CIRCULATIONAHA.108.839639

Duytschaever, 2018, PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial, Eur Heart J, 39, 1429, 10.1093/eurheartj/ehx666

Mardigyan, 2013, Anticoagulation management pre- and post atrial fibrillation ablation: a survey of Canadian centres, Can J Cardiol, 29, 219, 10.1016/j.cjca.2012.04.013

Nakahara, 2014, Epicardial adipose tissue-based defragmentation approach to persistent atrial fibrillation: its impact on complex fractionated electrograms and ablation outcome, Heart Rhythm, 11, 1343, 10.1016/j.hrthm.2014.04.040

Chao, 2013, Epicardial adipose tissue thickness and ablation outcome of atrial fibrillation, PLoS One, 8, e74926, 10.1371/journal.pone.0074926

Masuda, 2015, Abundant epicardial adipose tissue surrounding the left atrium predicts early rather than late recurrence of atrial fibrillation after catheter ablation, J Interv Card Electrophysiol, 44, 31, 10.1007/s10840-015-0031-3

Sepehri Shamloo, 2019, Is epicardial fat tissue associated with atrial fibrillation recurrence after ablation? A systematic review and meta-analysis, Int J Cardiol Heart Vasc, 22, 132

Blanche, 2013, Value of P-wave signal averaging to predict atrial fibrillation recurrences after pulmonary vein isolation, Europace, 15, 198, 10.1093/europace/eus251

Bhargava, 2009, Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study, Heart Rhythm, 6, 1403, 10.1016/j.hrthm.2009.06.014

Winkle, 2011, Long-term results of atrial fibrillation ablation: the importance of all initial ablation failures undergoing a repeat ablation, Am Heart J, 162, 193, 10.1016/j.ahj.2011.04.013

Mohanty, 2014, Long-term outcome of catheter ablation in atrial fibrillation patients with coexistent metabolic syndrome and obstructive sleep apnea: impact of repeat procedures versus lifestyle changes, J Cardiovasc Electrophysiol, 25, 930, 10.1111/jce.12468

Ejima, 2013, Impact of diastolic dysfunction on the outcome of catheter ablation in patients with atrial fibrillation, Int J Cardiol, 164, 88, 10.1016/j.ijcard.2011.06.093

Hocini, 2003, Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses, Circulation, 108, 1172, 10.1161/01.CIR.0000090685.13169.07

Chen, 2014, Pacing or ablation: which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome?, Pacing Clin Electrophysiol, 37, 403, 10.1111/pace.12340

Inada, 2014, The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-up, Europace, 16, 208, 10.1093/europace/eut159

Cummings, 2005, Left atrial flutter following pulmonary vein antrum isolation with radiofrequency energy: linear lesions or repeat isolation, J Cardiovasc Electrophysiol, 16, 293, 10.1046/j.1540-8167.2005.40585.x

Schneider, 2015, Pulmonary vein triggers play an important role in the initiation of atrial flutter: initial results from the prospective randomized Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial, Heart Rhythm, 12, 865, 10.1016/j.hrthm.2015.01.040

Patel, 2016, Contemporary utilization and safety outcomes of catheter ablation of atrial flutter in the United States: analysis of 89,638 procedures, Heart Rhythm, 13, 1317, 10.1016/j.hrthm.2016.02.005

Cox, 2000, The development of the maze procedure for the treatment of atrial fibrillation, Semin Thorac Cardiovasc Surg, 12, 2, 10.1016/S1043-0679(00)70010-4

Melby, 2006, A new era in the surgical treatment of atrial fibrillation: the impact of ablation technology and lesion set on procedural efficacy, Ann Surg, 244, 583

Badhwar, 2017, The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the surgical treatment of atrial fibrillation, Ann Thorac Surg, 103, 329, 10.1016/j.athoracsur.2016.10.076

Belley-Cote, 2019, Perspective and practice of surgical atrial fibrillation ablation: an international survey of cardiac surgeons, Europace, 21, 445, 10.1093/europace/euy212

Barnett, 2006, Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis, J Thorac Cardiovasc Surg, 131, 1029, 10.1016/j.jtcvs.2005.10.020

McClure, 2018, Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials, Europace, 20, 1442, 10.1093/europace/eux336

Osmancik, 2019, Five-year outcomes in cardiac surgery patients with atrial fibrillation undergoing concomitant surgical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 study, Heart Rhythm, 16, 1334, 10.1016/j.hrthm.2019.05.001

Sharples, 2018, Amaze: a double-blind, multicentre randomised controlled trial to investigate the clinical effectiveness and cost-effectiveness of adding an ablation device-based maze procedure as an adjunct to routine cardiac surgery for patients with pre-existing atrial fibrillation, Health Technol Assess, 22, 1, 10.3310/hta22190

Bagge, 2018, Quality of life is not improved after mitral valve surgery combined with epicardial left atrial cryoablation as compared with mitral valve surgery alone: a substudy of the double blind randomized SWEDish Multicentre Atrial Fibrillation study (SWEDMAF), Europace, 20, f343, 10.1093/europace/eux253

Suwalski, 2019, Surgical ablation for atrial fibrillation during isolated coronary artery bypass surgery, Eur J Cardiothorac Surg, 10.1093/ejcts/ezz298

Suwalski, 2018, Survival after surgical ablation for atrial fibrillation in mitral valve surgery: analysis from the Polish National Registry of Cardiac Surgery Procedures (KROK), J Thorac Cardiovasc Surg

Gillinov, 2006, Surgery for paroxysmal atrial fibrillation in the setting of mitral valve disease: a role for pulmonary vein isolation?, Ann Thorac Surg, 81, 19, 10.1016/j.athoracsur.2005.04.060

Basu, 2012, How effective is bipolar radiofrequency ablation for atrial fibrillation during concomitant cardiac surgery?, Interact Cardiovasc Thorac Surg, 15, 741, 10.1093/icvts/ivs311

Gillinov, 2006, Surgery for permanent atrial fibrillation: impact of patient factors and lesion set, Ann Thorac Surg, 82, 502, 10.1016/j.athoracsur.2006.02.030

Beukema, 2008, Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified maze procedure, Eur J Cardiothorac Surg, 34, 771, 10.1016/j.ejcts.2008.07.026

Lee, 2011, The influence of age on atrial fibrillation recurrence after the maze procedure in patients with giant left atrium, J Thorac Cardiovasc Surg, 141, 1015, 10.1016/j.jtcvs.2010.08.036

Damiano, 2011, The Cox maze IV procedure: predictors of late recurrence, J Thorac Cardiovasc Surg, 141, 113, 10.1016/j.jtcvs.2010.08.067

Sunderland, 2011, What size of left atrium significantly impairs the success of maze surgery for atrial fibrillation?, Interact Cardiovasc Thorac Surg, 13, 332, 10.1510/icvts.2011.271999

Bakker, 2013, Results of clinical application of the modified maze procedure as concomitant surgery, Interact Cardiovasc Thorac Surg, 16, 151, 10.1093/icvts/ivs440

Ad, 2014, Prediction of sinus rhythm in patients undergoing concomitant Cox maze procedure through a median sternotomy, J Thorac Cardiovasc Surg, 148, 881, 10.1016/j.jtcvs.2014.04.050

Blomstrom-Lundqvist, 2007, A randomized double-blind study of epicardial left atrial cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish Multicentre Atrial Fibrillation study (SWEDMAF), Eur Heart J, 28, 2902, 10.1093/eurheartj/ehm378

Huffman, 2016, Concomitant atrial fibrillation surgery for people undergoing cardiac surgery, Cochrane Database Syst Rev, CD011814

Budera, 2012, Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study, Eur Heart J, 33, 2644, 10.1093/eurheartj/ehs290

Wang, 2014, Ablation in selective patients with long-standing persistent atrial fibrillation: medium-term results of the Dallas lesion set, Eur J Cardiothorac Surg, 46, 213, 10.1093/ejcts/ezt593

Badhwar, 2017, Surgical ablation of atrial fibrillation in the United States: trends and propensity matched outcomes, Ann Thorac Surg, 104, 493, 10.1016/j.athoracsur.2017.05.016

Joshibayev, 2016, Early and long-term outcomes and quality of life after concomitant mitral valve surgery, left atrial size reduction, and radiofrequency surgical ablation of atrial fibrillation, Anatol J Cardiol, 16, 797

Driessen, 2018, Quality of life improves after thoracoscopic surgical ablation of advanced atrial fibrillation: results of the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (AFACT) study, J Thorac Cardiovasc Surg, 155, 972, 10.1016/j.jtcvs.2017.09.093

Castella, 2019, Thoracoscopic vs. catheter ablation for atrial fibrillation: long-term follow-up of the FAST randomized trial, Europace, 21, 746, 10.1093/europace/euy325

Osmancik, 2020, Improvement in the quality of life of patients with persistent or long-standing persistent atrial fibrillation after hybrid ablation, J Interv Card Electrophysiol, 10.1007/s10840-019-00546-7

Kim, 2016, Epicardial thoracoscopic ablation versus endocardial catheter ablation for management of atrial fibrillation: a systematic review and meta-analysis, Interact Cardiovasc Thorac Surg, 22, 729, 10.1093/icvts/ivw027

Gammie, 2008, Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons National Cardiac Database, Ann Thorac Surg, 85, 909, 10.1016/j.athoracsur.2007.10.097

Calkins, 2012, 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design, Europace, 14, 528, 10.1093/europace/eus027

van der Heijden, 2019, Hybrid versus catheter ablation in patients with persistent and longstanding persistent atrial fibrillation: a systematic review and meta-analysis, Eur J Cardiothorac Surg, 56, 433, 10.1093/ejcts/ezy475

Velagic, 2016, Repeat procedures after hybrid thoracoscopic ablation in the setting of longstanding persistent atrial fibrillation: electrophysiological findings and 2-year clinical outcome, J Cardiovasc Electrophysiol, 27, 41, 10.1111/jce.12837

Osmancik, 2016, Electrophysiological findings after surgical thoracoscopic atrial fibrillation ablation, Heart Rhythm, 13, 1246, 10.1016/j.hrthm.2016.02.007

Wang, 2018, A prospective randomized trial of the cut-and-sew maze procedure in patients undergoing surgery for rheumatic mitral valve disease, J Thorac Cardiovasc Surg, 155, 608, 10.1016/j.jtcvs.2017.07.084

Lawrance, 2014, A minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major morbidity and hospital stay, J Thorac Cardiovasc Surg, 148, 955, 10.1016/j.jtcvs.2014.05.064

Weimar, 2012, The Cox-maze procedure for lone atrial fibrillation: a single-center experience over 2 decades, Circ Arrhythm Electrophysiol, 5, 8, 10.1161/CIRCEP.111.963819

Nuotio, 2014, Time to cardioversion for acute atrial fibrillation and thromboembolic complications, JAMA, 312, 647, 10.1001/jama.2014.3824

Airaksinen, 2013, Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study, J Am Coll Cardiol, 62, 1187, 10.1016/j.jacc.2013.04.089

Hansen, 2015, Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy, Europace, 17, 18, 10.1093/europace/euu189

Lip, 1995, Cardioversion of atrial fibrillation, Postgrad Med J, 71, 457, 10.1136/pgmj.71.838.457

Garg, 2016, Incidence of thromboembolic complications within 30 days of electrical cardioversion performed within 48 hours of atrial fibrillation onset, JACC Clin Electrophysiol, 2, 487, 10.1016/j.jacep.2016.01.018

Tampieri, 2018, Safety of cardioversion in atrial fibrillation lasting less than 48 h without post-procedural anticoagulation in patients at low cardioembolic risk, Intern Emerg Med, 13, 87, 10.1007/s11739-016-1589-1

Klein, 2001, Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation, N Engl J Med, 344, 1411, 10.1056/NEJM200105103441901

Stellbrink, 2004, Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial, Circulation, 109, 997, 10.1161/01.CIR.0000120509.64740.DC

Cappato, 2014, Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation, Eur Heart J, 35, 3346, 10.1093/eurheartj/ehu367

Ezekowitz, 2018, Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial, Eur Heart J, 39, 2959, 10.1093/eurheartj/ehy148

Goette, 2016, Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial, Lancet, 388, 1995, 10.1016/S0140-6736(16)31474-X

Telles-Garcia, 2018, Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and meta-analysis, Int J Cardiol, 268, 143, 10.1016/j.ijcard.2018.04.034

Brunetti, 2018, Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis, J Thromb Thrombolysis, 45, 550, 10.1007/s11239-018-1622-5

Kotecha, 2018, Direct oral anticoagulants halve thromboembolic events after cardioversion of AF compared with warfarin, J Am Coll Cardiol, 72, 1984, 10.1016/j.jacc.2018.07.083

Itainen, 2018, Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion, Europace, 20, 565, 10.1093/europace/eux116

Lip, 2016, Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF, Am Heart J, 178, 126, 10.1016/j.ahj.2016.05.007

Steinberg, 2004, Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study, Circulation, 109, 1973, 10.1161/01.CIR.0000118472.77237.FA

Cardoso, 2018, An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation, Heart Rhythm, 15, 107, 10.1016/j.hrthm.2017.09.011

Calkins, 2017, Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation, N Engl J Med, 376, 1627, 10.1056/NEJMoa1701005

Cappato, 2015, Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation, Eur Heart J, 36, 1805, 10.1093/eurheartj/ehv177

Kirchhof, 2018, Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation, Eur Heart J, 39, 2942, 10.1093/eurheartj/ehy176

Hohnloser, 2019, Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial, Eur Heart J, 40, 3013, 10.1093/eurheartj/ehz190

Camm, 2010, Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC), Eur Heart J, 31, 2369, 10.1093/eurheartj/ehq278

Lafuente-Lafuente, 2012, Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation, Cochrane Database Syst Rev, CD005049

Valembois, 2019, Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation, Cochrane Database Syst Rev, 9, CD005049

Nabauer, 2009, The registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management, Europace, 11, 423, 10.1093/europace/eun369

Darkner, 2014, Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial), Eur Heart J, 35, 3356, 10.1093/eurheartj/ehu354

Leong-Sit, 2011, Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study): six-month follow-up study, Circ Arrhythm Electrophysiol, 4, 11, 10.1161/CIRCEP.110.955393

Abed, 2013, Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial, JAMA, 310, 2050, 10.1001/jama.2013.280521

Pathak, 2015, Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY), J Am Coll Cardiol, 65, 2159, 10.1016/j.jacc.2015.03.002

Lafuente-Lafuente, 2015, Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation, Cochrane Database Syst Rev, 3, CD005049

Kochiadakis, 2000, Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study, Heart, 84, 251, 10.1136/heart.84.3.251

Galperin, 2001, Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial, J Cardiovasc Pharmacol Ther, 6, 341, 10.1177/107424840100600403

Channer, 2004, A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation, Eur Heart J, 25, 144, 10.1016/j.ehj.2003.10.020

Singh, 2003, Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T, Am J Cardiol, 92, 468, 10.1016/S0002-9149(03)00671-4

Kochiadakis, 2004, Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation, Am J Cardiol, 94, 1563, 10.1016/j.amjcard.2004.08.041

Gulizia, 2008, A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial, Am Heart J, 155, 100, 10.1016/j.ahj.2007.08.033

Freemantle, 2011, Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation, Europace, 13, 329, 10.1093/europace/euq450

Cadrin-Tourigny, 2014, Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials, J Cardiovasc Electrophysiol, 25, 1306, 10.1111/jce.12535

Massie, 1996, Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators, Circulation, 93, 2128, 10.1161/01.CIR.93.12.2128

Singh, 1995, Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure, N Engl J Med, 333, 77, 10.1056/NEJM199507133330201

Zimetbaum, 2012, Antiarrhythmic drug therapy for atrial fibrillation, Circulation, 125, 381, 10.1161/CIRCULATIONAHA.111.019927

Kirchhof, 2009, Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation, J Am Coll Cardiol, 54, 143, 10.1016/j.jacc.2009.03.043

Orr, 2009, Frequency, characteristics, and risk factors for amiodarone neurotoxicity, Arch Neurol, 66, 865, 10.1001/archneurol.2009.96

Lai, 2015, Amiodarone use and risk of acute pancreatitis: a population-based case-control study, Heart Rhythm, 12, 163, 10.1016/j.hrthm.2014.08.037

Epstein, 2016, Practical management guide for clinicians who treat patients with amiodarone, Am J Med, 129, 468, 10.1016/j.amjmed.2015.08.039

Basaria, 2005, Amiodarone and the thyroid, Am J Med, 118, 706, 10.1016/j.amjmed.2004.11.028

Colby, 2017, Amiodarone-induced pulmonary toxicity, JAAPA, 30, 23, 10.1097/01.JAA.0000524713.17719.c8

Van Gelder, 1989, Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter, Am J Cardiol, 64, 1317, 10.1016/0002-9149(89)90574-2

Anderson, 1989, Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group, Circulation, 80, 1557, 10.1161/01.CIR.80.6.1557

Stroobandt, 1997, Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators, Am J Cardiol, 79, 418, 10.1016/S0002-9149(96)00779-5

Echt, 1991, Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial, N Engl J Med, 324, 781, 10.1056/NEJM199103213241201

Flaker, 1992, Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators, J Am Coll Cardiol, 20, 527, 10.1016/0735-1097(92)90003-6

Podrid, 1996, Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The Propafenone Multicenter Study Group, Am J Cardiol, 78, 430, 10.1016/S0002-9149(96)00332-3

Brembilla-Perrot, 2013, 1: 1 atrial-flutter. Prevalence and clinical characteristics, Int J Cardiol, 168, 3287, 10.1016/j.ijcard.2013.04.047

Gao, 2018, Initiation and outcomes with Class Ic antiarrhythmic drug therapy, Indian Pacing Electrophysiol J, 18, 68, 10.1016/j.ipej.2017.12.001

Richiardi, 1992, [Propafenone versus hydroquinidine in long-term pharmacological prophylaxis of atrial fibrillation], Cardiologia, 37, 123

Chimienti, 1996, Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: report from the, Am J Cardiol, 77, 60A, 10.1016/S0002-9149(97)89119-9

Reimold, 1993, Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation, Am J Cardiol, 71, 558, 10.1016/0002-9149(93)90511-A

Aliot, 1996, Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group, Am J Cardiol, 77, 66A, 10.1016/S0002-9149(97)89120-5

Bellandi, 2001, Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation, Am J Cardiol, 88, 640, 10.1016/S0002-9149(01)01806-9

Meinertz, 2002, Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study), Am J Cardiol, 90, 1300, 10.1016/S0002-9149(02)02867-9

Pritchett, 2003, Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation, Am J Cardiol, 92, 941, 10.1016/S0002-9149(03)00974-3

Hohnloser, 2009, Effect of dronedarone on cardiovascular events in atrial fibrillation, N Engl J Med, 360, 668, 10.1056/NEJMoa0803778

Le Heuzey, 2010, A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study, J Cardiovasc Electrophysiol, 21, 597, 10.1111/j.1540-8167.2010.01764.x

Singh, 2007, Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter, N Engl J Med, 357, 987, 10.1056/NEJMoa054686

Touboul, 2003, Dronedarone for prevention of atrial fibrillation: a dose-ranging study, Eur Heart J, 24, 1481, 10.1016/S0195-668X(03)00321-X

Kober, 2008, Dronedarone Study G. Increased mortality after dronedarone therapy for severe heart failure, N Engl J Med, 358, 2678, 10.1056/NEJMoa0800456

Wu, 2018, Assessing the risk for peripheral neuropathy in patients treated with dronedarone compared with that in other antiarrhythmics, Clin Ther, 40, 450, 10.1016/j.clinthera.2018.01.015

Piccini, 2009, Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation, J Am Coll Cardiol, 54, 1089, 10.1016/j.jacc.2009.04.085

Gao, 2013, Risk of cardiovascular events, stroke, congestive heart failure, interstitial lung disease, and acute liver injury: dronedarone versus amiodarone and other antiarrhythmics, J Atr Fibrillation, 6, 890

Pisters, 2014, Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial, Europace, 16, 174, 10.1093/europace/eut293

Connolly, 2011, Dronedarone in high-risk permanent atrial fibrillation, N Engl J Med, 365, 2268, 10.1056/NEJMoa1109867

Friberg, 2014, Safety of dronedarone in routine clinical care, J Am Coll Cardiol, 63, 2376, 10.1016/j.jacc.2014.02.601

Friberg, 2018, Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs, Am Heart J, 205, 118, 10.1016/j.ahj.2018.06.018

Khan, 2017, Efficacy and safety of dronedarone in the treatment of patients with atrial fibrillation, Expert Opin Drug Saf, 16, 1407, 10.1080/14740338.2017.1387246

Vamos, 2016, Amiodarone and dronedarone: an update, Trends Cardiovasc Med, 26, 597, 10.1016/j.tcm.2016.03.014

Tschuppert, 2007, Effect of dronedarone on renal function in healthy subjects, Br J Clin Pharmacol, 64, 785, 10.1111/j.1365-2125.2007.02998.x

Vijayalakshmi, 2006, randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned, Am Heart J, 151, 863.e1-6, 10.1016/j.ahj.2005.09.009

Capucci, 2008, The Drug And Pace Health cliNical Evaluation (DAPHNE) study: a randomized trial comparing sotalol versus beta-blockers to treat symptomatic atrial fibrillation in patients with brady-tachycardia syndrome implanted with an antitachycardia pacemaker, Am Heart J, 156, 373.e1-8, 10.1016/j.ahj.2008.01.032

Juul-Moller, 1990, Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation, Circulation, 82, 1932, 10.1161/01.CIR.82.6.1932

MacNeil, 1993, Clinical safety profile of sotalol in the treatment of arrhythmias, Am J Cardiol, 72, 44A, 10.1016/0002-9149(93)90024-7

Roy, 2000, Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators, N Engl J Med, 342, 913, 10.1056/NEJM200003303421302

Andersen, 2009, Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study, Europace, 11, 886, 10.1093/europace/eup119

Crijns, 1996, Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group, Cardiovasc Drugs Ther, 10, 145, 10.1007/BF00823592

Lloyd, 1984, The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. A double-blind study comparing quinidine, disopyramide and placebo, S Afr Med J, 65, 367

Karlson, 1988, Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study, Eur Heart J, 9, 284, 10.1093/oxfordjournals.eurheartj.a062498

Coplen, 1990, Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials, Circulation, 82, 1106, 10.1161/01.CIR.82.4.1106

Lip, 2014, A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) pilot general registry, Europace, 16, 308, 10.1093/europace/eut373

Dagres, 2013, Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: the European Heart Rhythm Association survey, Europace, 15, 478, 10.1093/europace/eut063

Sherrid, 2005, Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy, J Am Coll Cardiol, 45, 1251, 10.1016/j.jacc.2005.01.012

Goette, 2000, Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation, J Am Coll Cardiol, 35, 1669, 10.1016/S0735-1097(00)00611-2

Thanigaimani, 2017, Molecular mechanisms of atrial fibrosis: implications for the clinic, Expert Rev Cardiovasc Ther, 15, 247, 10.1080/14779072.2017.1299005

Kumagai, 2003, Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation, J Am Coll Cardiol, 41, 2197, 10.1016/S0735-1097(03)00464-9

Schneider, 2010, Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis, J Am Coll Cardiol, 55, 2299, 10.1016/j.jacc.2010.01.043

Healey, 2005, Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis, J Am Coll Cardiol, 45, 1832, 10.1016/j.jacc.2004.11.070

Ducharme, 2006, Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program, Am Heart J, 152, 86, 10.1016/j.ahj.2005.06.036

McMurray, 2006, Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial, Am Heart J, 151, 985, 10.1016/j.ahj.2006.02.028

Wachtell, 2005, Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study, J Am Coll Cardiol, 45, 712, 10.1016/j.jacc.2004.10.068

Anand, 2006, Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation, Am Heart J, 152, 217, 10.1016/j.ahj.2006.01.007

Okin, 2006, Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension, JAMA, 296, 1242, 10.1001/jama.296.10.1242

Olsson, 2006, Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program, J Am Coll Cardiol, 47, 1997, 10.1016/j.jacc.2006.01.060

Marott, 2014, Antihypertensive treatment and risk of atrial fibrillation: a nationwide study, Eur Heart J, 35, 1205, 10.1093/eurheartj/eht507

Goette, 2012, Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial, Circ Arrhythm Electrophysiol, 5, 43, 10.1161/CIRCEP.111.965178

Savelieva, 2011, Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention, Europace, 13, 610, 10.1093/europace/eur023

Reil, 2012, Aldosterone promotes atrial fibrillation, Eur Heart J, 33, 2098, 10.1093/eurheartj/ehr266

Reil, 2016, Hyperaldosteronism induces left atrial systolic and diastolic dysfunction, Am J Physiol Heart Circ Physiol, 311, H1014, 10.1152/ajpheart.00261.2016

Tsai, 2010, Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation, J Am Coll Cardiol, 55, 758, 10.1016/j.jacc.2009.09.045

Pitt, 2003, Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 348, 1309, 10.1056/NEJMoa030207

Swedberg, 2012, Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study, J Am Coll Cardiol, 59, 1598, 10.1016/j.jacc.2011.11.063

Cikes, 2018, Atrial fibrillation in heart failure with preserved ejection fraction: the TOPCAT trial, JACC Heart Fail, 6, 689, 10.1016/j.jchf.2018.05.005

Neefs, 2017, Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis, Int J Cardiol, 231, 155, 10.1016/j.ijcard.2016.12.029

Kuhlkamp, 2000, Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study, J Am Coll Cardiol, 36, 139, 10.1016/S0735-1097(00)00693-8

Nergardh, 2007, Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study, Eur Heart J, 28, 1351, 10.1093/eurheartj/ehl544

Zheng, 2016, Perioperative rosuvastatin in cardiac surgery, N Engl J Med, 374, 1744, 10.1056/NEJMoa1507750

Rahimi, 2011, Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials, BMJ, 342, d1250, 10.1136/bmj.d1250

Pinho-Gomes, 2014, Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins, Antioxid Redox Signal, 20, 1268, 10.1089/ars.2013.5542

Humphries, 2007, Statin use and recurrence of atrial fibrillation after successful cardioversion, Am Heart J, 154, 908, 10.1016/j.ahj.2007.07.015

Bianconi, 2011, n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study, Europace, 13, 174, 10.1093/europace/euq386

Mozaffarian, 2012, Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial, JAMA, 308, 2001, 10.1001/jama.2012.28733

Yamashita, 2011, Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study, Europace, 13, 473, 10.1093/europace/euq439

Macchia, 2013, Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial, J Am Coll Cardiol, 61, 463, 10.1016/j.jacc.2012.11.021

Kowey, 2010, Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial, JAMA, 304, 2363, 10.1001/jama.2010.1735

Kochiadakis, 2000, Amiodarone, sotalol, or propafenone in atrial fibrillation: which is preferred to maintain normal sinus rhythm?, Pacing Clin Electrophysiol, 23, 1883, 10.1111/j.1540-8159.2000.tb07044.x

Boriani, 1997, Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial, Ann Intern Med, 126, 621, 10.7326/0003-4819-126-8-199704150-00006

Ehrlich, 2019, Impact of dronedarone on the risk of myocardial infarction and stroke in atrial fibrillation patients followed in general practices in Germany, Int J Cardiol, 278, 126, 10.1016/j.ijcard.2018.11.133

Camm, 2017, Hopes and disappointments with antiarrhythmic drugs, Int J Cardiol, 237, 71, 10.1016/j.ijcard.2017.03.056

De Vecchis, 2019, Long-term antiarrhythmic drug treatment after atrial fibrillation ablation: does a too obstinate rhythm control strategy bring serious risk of proarrhythmia to ablated patients?, Eur Heart J Cardiovasc Pharmacother, 5, 117, 10.1093/ehjcvp/pvy043

Fabritz, 2010, Predictable and less predictable unwanted cardiac drugs effects: individual pre-disposition and transient precipitating factors, Basic Clin Pharmacol Toxicol, 106, 263, 10.1111/j.1742-7843.2010.00547.x

Reimold, 2018, Proarrhythmia and death with antiarrhythmic drugs for atrial fibrillation, and the unfulfilled promise of comparative effectiveness research, Am Heart J, 205, 128, 10.1016/j.ahj.2018.08.011

Coughtrie, 2017, Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort, BMJ Open, 7, e016627, 10.1136/bmjopen-2017-016627

Haverkamp, 2000, The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology, Eur Heart J, 21, 1216, 10.1053/euhj.2000.2249

Milan, 2017, Efficacy of intravenous and oral sotalol in pharmacologic conversion of atrial fibrillation: a systematic review and meta-analysis, Cardiology, 136, 52, 10.1159/000447237

Agusala, 2015, Risk prediction for adverse events during initiation of sotalol and dofetilide for the treatment of atrial fibrillation, Pacing Clin Electrophysiol, 38, 490, 10.1111/pace.12586

Lin, 2015, Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart, Heart Rhythm, 12, 1490, 10.1016/j.hrthm.2015.04.018

Kaab, 2003, Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome – a case-control pilot study using i.v. sotalol, Eur Heart J, 24, 649, 10.1016/S0195-668X(02)00806-0

Lehtonen, 2007, Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes, Heart Rhythm, 4, 603, 10.1016/j.hrthm.2007.01.019

Patten, 2004, Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial, Eur Heart J, 25, 1395, 10.1016/j.ehj.2004.06.014

Fetsch, 2004, Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial, Eur Heart J, 25, 1385, 10.1016/j.ehj.2004.04.015

Vallurupalli, 2015, Utility of routine exercise testing to detect rate-related QRS widening in patients without structural heart disease on class Ic antiarrhythmic agents (flecainide and propafenone), Am J Cardiol, 116, 730, 10.1016/j.amjcard.2015.05.039

Parkash, 2017, Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: a randomized, open-label clinical trial (SMAC-AF [Substrate Modification With Aggressive Blood Pressure Control]), Circulation, 135, 1788, 10.1161/CIRCULATIONAHA.116.026230

Huxley, 2014, Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study, Circ Arrhythm Electrophysiol, 7, 620, 10.1161/CIRCEP.113.001244

Murphy, 2006, Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study), Eur Heart J, 27, 96, 10.1093/eurheartj/ehi506

Wanahita, 2008, Atrial fibrillation and obesity – results of a meta-analysis, Am Heart J, 155, 310, 10.1016/j.ahj.2007.10.004

Wang, 2004, Obesity and the risk of new-onset atrial fibrillation, JAMA, 292, 2471, 10.1001/jama.292.20.2471

Baek, 2017, Associations of abdominal obesity and new-onset atrial fibrillation in the general population, J Am Heart Assoc, 6, 10.1161/JAHA.116.004705

Proietti, 2017, Is there an obesity paradox for outcomes in atrial fibrillation? A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant trials, Stroke, 48, 857, 10.1161/STROKEAHA.116.015984

Piepoli, 2016, 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur Heart J, 37, 2315, 10.1093/eurheartj/ehw106

Cha, 2008, Catheter ablation for atrial fibrillation in patients with obesity, Circulation, 117, 2583, 10.1161/CIRCULATIONAHA.107.716712

Ector, 2007, Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for atrial fibrillation, J Am Coll Cardiol, 50, 234, 10.1016/j.jacc.2007.03.040

Shoemaker, 2013, Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation, Am J Cardiol, 111, 368, 10.1016/j.amjcard.2012.10.013

Ettinger, 1978, Arrhythmias and the ‘holiday heart’: alcohol-associated cardiac rhythm disorders, Am Heart J, 95, 555, 10.1016/0002-8703(78)90296-X

Conen, 2014, Alcohol consumption and risk of atrial fibrillation: how much is too much?, J Am Coll Cardiol, 64, 290, 10.1016/j.jacc.2014.04.038

Liang, 2012, Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease, CMAJ, 184, E857, 10.1503/cmaj.120412

Larsson, 2014, Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis, J Am Coll Cardiol, 64, 281, 10.1016/j.jacc.2014.03.048

Overvad, 2013, Alcohol intake and prognosis of atrial fibrillation, Heart, 99, 1093, 10.1136/heartjnl-2013-304036

Voskoboinik, 2020, Alcohol abstinence in drinkers with atrial fibrillation, N Engl J Med, 382, 20, 10.1056/NEJMoa1817591

Lavie, 2009, Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease, Mayo Clin Proc, 84, 373, 10.1016/S0025-6196(11)60548-X

Mont, 2010, Arrhythmias and sport practice, Heart, 96, 398, 10.1136/hrt.2008.160903

Menezes, 2015, Lifestyle modification in the prevention and treatment of atrial fibrillation, Prog Cardiovasc Dis, 58, 117, 10.1016/j.pcad.2015.07.001

Karjalainen, 1998, Lone atrial fibrillation in vigorously exercising middle aged men: case-control study, BMJ, 316, 1784, 10.1136/bmj.316.7147.1784

Baldesberger, 2008, Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists, Eur Heart J, 29, 71, 10.1093/eurheartj/ehm555

Molina, 2008, Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study, Europace, 10, 618, 10.1093/europace/eun071

Nielsen, 2013, The relationship between physical activity and risk of atrial fibrillation – a systematic review and meta-analysis, J Atr Fibrillation, 5, 789

Risom, 2017, Exercise-based cardiac rehabilitation for adults with atrial fibrillation, Cochrane Database Syst Rev, 2, CD011197

Dzeshka, 2017, Atrial fibrillation and hypertension, Hypertension, 70, 854, 10.1161/HYPERTENSIONAHA.117.08934

Williams, 2018, 2018 ESC/ESH Guidelines for the management of arterial hypertension, Eur Heart J, 39, 3021, 10.1093/eurheartj/ehy339

Kim, 2019, Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population, Eur Heart J, 40, 809, 10.1093/eurheartj/ehy877

Lip, 2007, Effect of hypertension on anticoagulated patients with atrial fibrillation, Eur Heart J, 28, 752, 10.1093/eurheartj/ehl504

Steinberg, 2020, Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF randomized clinical trial, JAMA, 323, 248, 10.1001/jama.2019.21187

Du, 2009, Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study, Eur Heart J, 30, 1128, 10.1093/eurheartj/ehp055

Pallisgaard, 2016, Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study, Eur J Prev Cardiol, 23, 621, 10.1177/2047487315599892

Rizzo, 2015, Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes, J Diabetes Complications, 29, 88, 10.1016/j.jdiacomp.2014.09.002

Movahed, 2005, Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease, Int J Cardiol, 105, 315, 10.1016/j.ijcard.2005.02.050

Lee, 2016, Evaluation of the association between diabetic retinopathy and the incidence of atrial fibrillation: a nationwide population-based study, Int J Cardiol, 223, 953, 10.1016/j.ijcard.2016.08.296

Mozaffarian, 2015, Heart disease and stroke statistics – 2015 update: a report from the American Heart Association, Circulation, 131, e29

Fatemi, 2014, Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes study), Am J Cardiol, 114, 1217, 10.1016/j.amjcard.2014.07.045

Chang, 2014, Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies, Cardiovasc Diabetol, 13, 123, 10.1186/s12933-014-0123-x

Zhang, 2017, Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis, BMC Cardiovasc Disord, 17, 96, 10.1186/s12872-017-0531-4

Bell, 2019, Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies, Diabetes Obes Metab, 21, 210, 10.1111/dom.13512

Patti, 2017, Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials, Diabetes Metab Res Rev, 33, 10.1002/dmrr.2876

Hylek, 2014, Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes, J Am Coll Cardiol, 63, 2141, 10.1016/j.jacc.2014.02.549

Donnellan, 2019, Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation, JACC Clin Electrophysiol, 5, 897, 10.1016/j.jacep.2019.05.018

Linz, 2018, Doug McEvoy R. Assessment and interpretation of sleep disordered breathing severity in cardiology: clinical implications and perspectives, Int J Cardiol, 271, 281, 10.1016/j.ijcard.2018.04.076

Gami, 2004, Association of atrial fibrillation and obstructive sleep apnea, Circulation, 110, 364, 10.1161/01.CIR.0000136587.68725.8E

Goudis, 2017, Obstructive sleep and atrial fibrillation: pathophysiological mechanisms and therapeutic implications, Int J Cardiol, 230, 293, 10.1016/j.ijcard.2016.12.120

Epstein, 2009, Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults, J Clin Sleep Med, 5, 263, 10.5664/jcsm.27497

Linz, 2018, Associations of obstructive sleep apnea with atrial fibrillation and continuous positive airway pressure treatment: a review, JAMA Cardiol, 3, 532, 10.1001/jamacardio.2018.0095

Fein, 2013, Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation, J Am Coll Cardiol, 62, 300, 10.1016/j.jacc.2013.03.052

Neilan, 2013, Effect of sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial fibrillation, J Am Heart Assoc, 2, e000421, 10.1161/JAHA.113.000421

Qureshi, 2015, Meta-analysis of continuous positive airway pressure as a therapy of atrial fibrillation in obstructive sleep apnea, Am J Cardiol, 116, 1767, 10.1016/j.amjcard.2015.08.046

Shukla, 2015, Effect of obstructive sleep apnea treatment on atrial fibrillation recurrence: a meta-analysis, JACC Clin Electrophysiol, 1, 41, 10.1016/j.jacep.2015.02.014

Pathak, 2015, Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: the CARDIO-FIT study, J Am Coll Cardiol, 66, 985, 10.1016/j.jacc.2015.06.488

Bonfanti, 2019, Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience, Clin Exp Emerg Med, 6, 64, 10.15441/ceem.17.286

Scheuermeyer, 2012, Thirty-day and 1-year outcomes of emergency department patients with atrial fibrillation and no acute underlying medical cause, Ann Emerg Med, 60, 755, 10.1016/j.annemergmed.2012.05.007

Boriani, 2018, Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry, Int J Cardiol, 271, 68, 10.1016/j.ijcard.2018.05.034

Boriani, 2016, Real-world’ management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) general pilot registry, Europace, 18, 648, 10.1093/europace/euv390

Gulizia, 2019, Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study, Europace, 21, 230, 10.1093/europace/euy166

Gonzalez-Pacheco, 2015, Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation, J Cardiol, 66, 148, 10.1016/j.jjcc.2014.11.001

Krijthe, 2013, Unrecognized myocardial infarction and risk of atrial fibrillation: the Rotterdam Study, Int J Cardiol, 168, 1453, 10.1016/j.ijcard.2012.12.057

Chao, 2014, Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study, Heart Rhythm, 11, 1941, 10.1016/j.hrthm.2014.08.003

Sanclemente, 2014, Predictors of outcome in stable outpatients with peripheral artery disease, Intern Emerg Med, 9, 69, 10.1007/s11739-012-0854-1

Soliman, 2015, Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 131, 1843, 10.1161/CIRCULATIONAHA.114.014145

Soliman, 2014, Atrial fibrillation and the risk of myocardial infarction, JAMA Intern Med, 174, 107, 10.1001/jamainternmed.2013.11912

Kralev, 2011, Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography, PLoS One, 6, e24964, 10.1371/journal.pone.0024964

Guimaraes, 2019, Usefulness of antithrombotic therapy in patients with atrial fibrillation and acute myocardial infarction, Am J Cardiol, 123, 12, 10.1016/j.amjcard.2018.09.031

Erez, 2017, Temporal trends and outcomes associated with atrial fibrillation observed during acute coronary syndrome: real-world data from the Acute Coronary Syndrome Israeli Survey (ACSIS), 2000–2013, Clin Cardiol, 40, 275, 10.1002/clc.22654